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Preface
This Habilitation is based on selected publications, which represent my major sci-
entific contributions as an experimental physicist to the field of particle accelerators
and detectors applied to medical diagnostics and therapy. They are reprinted in
Part II of this work to be considered for the Habilitation and they cover original
achievements and relevant aspects for the present and future of medical applications
of particle physics.
The text reported in Part I is aimed at putting my scientific work into its con-
text and perspective, to comment on recent developments and, in particular, on my
contributions to the advances in accelerators and detectors for cancer hadrontherapy
and for the production of radioisotopes.
Dr. Saverio Braccini
Bern, 25.4.2013
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Introduction
Particle accelerators and detectors are fundamental instruments in modern medicine
to study the human body, to detect and cure its diseases. In the recent years, they
reached a high level of sophistication that allowed not only for great discoveries in
fundamental physics but also for impressive advances in medical diagnostics and
therapy.
Instrumentation issued from fundamental research in physics can be found today
in any hospital and nowadays-common medical practices were not even imaginable
only a few years ago. While many applications are well established, many others are
the focus of scientific research and innovative ideas are continuously appearing at the
horizon. In particular, particle accelerators and detectors for cancer hadrontherapy
and for the production of isotopes for functional imaging represent cutting-edge fields
at the forefront of science and technology. Many disciplines are necessarily involved
and common efforts from scientists active in research fields such as physics, chemistry,
engineering, biology, pharmacy and medicine are necessary not only to pursue knowl-
edge but also to make new diagnostic and treatment modalities routinely available
for patients.
In this dynamic and stimulating context, experimental particle physicists can
give decisive contributions and bring new ideas through their expertise acquired in
fundamental research. This is the main reason why, after having been involved in
several experimental particle physics projects at CERN, I have decided ten years ago
to focus my scientific efforts on medical applications of physics. It is in the field of
particle accelerators and detectors for cancer hadrontherapy and for the production
of radioisotopes where I gave my major contributions, and this Habilitation thesis is
therefore centred on the achievements in these specific domains.
Accelerated beams of charged hadrons, protons and carbon ions in particular,
allow the treatment of solid tumours by external irradiation with unprecedented
precision. This modality of radiation therapy is denominated hadrontherapy. To
exploit at best the physical and radiobiological properties of charged ions, the de-
velopment of high performance accelerators and detectors is crucial. In particular,
active beam scanning techniques allow painting the target volume with millimetre
precision and innovative systems are under study to optimize the performance and
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to reduce the size and the complexity of the treatment facilities. Proton and ion
linear accelerators (linacs) represent a promising solution to face the challenges of
hadrontherapy and, as reported in the first paper reprinted in Chapter 4, their use is
proposed for advanced beam scanning. Furthermore, as described in the second pa-
per of Chapter 4, linacs can be coupled to cyclotrons used for other medical purposes,
such as the production of radioisotopes for functional imaging or for the production
of beams of lower energy carbon ions. This new kind of hybrid accelerator is de-
nominated Cyclinac. The experience I acquired in the study and in the design of
Cyclinacs allowed me in 2007 to be one of the proponents of the new cyclotron labo-
ratory located at the Inselspital, the University Hospital in Bern. This new centre is
conceived for top-level radioisotope production for Positron Emission Tomography
(PET) and multi-disciplinary research running in parallel by means of a specifically
conceived beam transfer line (BTL) terminated in a separate bunker. As reported in
the third and fourth publication of Chapter 4, the BTL represents a peculiar feature
for a hospital-based cyclotron facility. The Bern cyclotron and its beam line were
designed, constructed, and commissioned under my coordination. This laboratory,
whose beam line is a unique facility in Switzerland, is now fully operational and the
first research programs are ongoing.
Highly performing particle detectors are crucial for scientific research as well as for
applications. In particular, the accurate monitoring of the beams during irradiations
for medical purposes is of prime importance. In hadrontherapy, the precise on-line
measurement of the position, the intensity and the shape of the clinical beams is
crucial, together with the knowledge of the range of the accelerated ions. To address
these problems, I contributed to design, develop and test three novel particle detec-
tors, as reported in the publications reprinted in Chapter 5. Segmented ionization
chambers constitute an effective solution for on-line monitoring of the clinical beams
during hadrontherapy treatments, especially in the case of spot scanning. These de-
velopments led to the conception and to the construction of a specific strip ionization
chamber developed for the Gantry 2 at the Paul Scherrer Institute (PSI), the most
advanced centre for spot scanning worldwide. In hadrontherapy, the dose given to the
healthy tissues surrounding the tumour has to be minimized and methods are under
study to improve the knowledge of the particle range; Proton radiography is one of
the most promising ones and we developed at LHEP an innovative technique based
on nuclear emulsion films. Furthermore, ion beams have to be precisely controlled
along the beam lines, either for hadrontherapy or for the production of isotopes. For
this purpose, I proposed a new device based on doped silica and optical fibres. The
first prototype is installed on the research beam line of the Bern cyclotron laboratory
and is performing already to specifications.
The present document is structured into two parts, each containing three Chap-
ters. In Part I, Chapter 1 presents an introduction to accelerators and detectors
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applied to medicine, with particular focus on cancer hadrontherapy and on the pro-
duction of radioactive isotopes. In Chapter 2, my publications on medical particle
accelerators are introduced and put into their perspective. In particular, high fre-
quency linear accelerators for hadrontherapy are discussed together with the new
Bern cyclotron laboratory. Chapter 3 is dedicated to particle detectors with partic-
ular emphasis on the three instruments I contributed to propose and develop. In
Part II, the mentioned publications are reprinted in Chapters 4 and 5, together with
three review papers on the present and future of cancer hadrontherapy reprinted in
Chapter 6.
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Part I
5

Chapter 1
Particle Accelerators and
Detectors applied to Medicine
The applications of nuclear and particle physics are fundamental in modern medicine
and deeply influenced its development. In particular, the conception and the real-
ization of specific particle accelerators and detectors determined crucial advances in
medical imaging and cancer radiation therapy. These instruments are today at the
basis of scientific progress in these domains.
Since the very beginning at the end of the nineteenth century, radiation sources of
increasing energy and power together with specific instruments to detect subatomic
particles led to great discoveries in fundamental physics and, in parallel, to revo-
lutionary and often unexpected medical applications. These developments changed
the life of many individuals and produced a direct benefit to the society. A textbook
example is the discovery of X-rays by Wilhelm Conrad Ro¨ntgen in 1895 [1]. Only
one month after the first observation of this new and at that time mysterious kind
of penetrating radiation, Ro¨ntgen had the idea that different tissues of the human
body could be characterized by different stopping capabilities. This intuition is at
the basis of the first radiography, which is reported in Fig. 1.1 (left). Already a few
months after the discovery, this novel clinical methodology allowed saving a large
number of human lives, especially in battlefields. Radiography surely represents the
first fundamental contribution of radiation physics to medicine and the beginning of
a fascinating scientific adventure, which is still continuing nowadays.
Right after the discovery of X-rays, many fundamental findings followed, opening
the way to the understanding of the structure of matter and of its fundamental inter-
actions. In 1896, natural radioactivity was discovered in uranium minerals by Henri
Becquerel [2] and, two years later, polonium and radium were discovered by Pierre
Curie and Maria Sk lodowska Curie [3]. Although the effects of ionizing radiations in
biological tissues were not known at that time, the idea of using radiations to cure
cancer was soon conceived and some superficial tumours were successfully treated
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Figure 1.1: The paper announcing the discovery of X-rays made by W. C. Ro¨ntgen
in November 1895 already contains their first medical application, the radiography of
the hand of his wife obtained only one month later, in December 1895 (left). Ernest
and John Lawrence performed the first salivary gland cancer treatments using one
of the first cyclotrons in 1936 (right).
by applying a radium source directly in contact with the skin. These pioneering
treatments signed the beginning of cancer radiation therapy. A basic problem came
out immediately: to be effective, radiations must be selectively directed towards the
tumour target, sparing at best the surrounding healthy tissues. This concept is today
called local control and represents the driving force that, from these first attempts,
brought to the most recent developments in cancer radiation therapy as, for example,
the use of precise pencil proton or ion beams in cancer hadrontherapy.
The first medical application of ion accelerators came only a few years after the
conception and construction of the first cyclotron by Ernest Lawrence and Stan Liv-
ingston in 1931 [4]. John Lawrence - medical doctor and brother of Ernest - injected
into humans an isotope of phosphorus - the β− emitter 32P - produced with one of
the first cyclotrons to cure leukaemia. These early clinical studies signed the birth of
nuclear medicine. Furthermore, the Lawrence brothers irradiated patients affected
by salivary gland tumours using neutron beams produced by 5 MeV accelerated
deuterons on a beryllium target [5], as shown in Fig. 1.1 (right). Since fast neutrons
produce nuclear fragments, these treatments represent the first use of ions in cancer
therapy.
In the same years, the discovery of the properties of slow neutrons in inducing
radioactivity in matter by Enrico Fermi and his group in Rome in 1934 [6] opened
the way not only to nuclear energy but also to large productions of radioisotopes
for medicine. In 1935, George Charles de Hevesy performed the first studies on the
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metabolism of rats using 32P [7], demonstrating that the formation of bones is a
dynamic process in which about 30% of the phosphorus in the skeleton is replaced in
about twenty days. This pioneering studies paved the way for the use of artificially
produced radioactive isotopes in life sciences.
The discovery of 99mTc by Emilio Segre` and Glenn Seaborg [8] in 1938 has been
fundamental for nuclear medicine. This isotope is characterized by a half-life of 6
hours and is naturally produced by the decay of 99Mo, which has a much longer half-
life of 66 hours. This allows the realization of 99Mo-99mTc generators [9], which make
99mTc daily available in hospitals. The conception of the gamma camera detector [10]
and the development of a large variety of technetium based compounds led to the
large diffusion of Single Photon Emission Tomography (SPECT), which accounts
today for more that 80% of the examinations in nuclear medicine.
With the aim of producing high-energy electron beams for fundamental physics,
in 1947 William Hansen, together with the brothers Sigurd and Russel Varian [11],
developed the first linear electron accelerator, which is today the main instrument
used in cancer radiation therapy. All modern hospitals are in fact equipped with
one or more of these devices and about twenty thousands patients every ten million
inhabitants are treated every year by means of these machines in western countries.
It is interesting to remark that of the about twenty thousands accelerators nowadays
running in the world, about one half are linacs used in radiation therapy [12].
From the first Geiger-Mu¨ller tubes developed in 1908 [13], particle detectors un-
derwent a continuous progress that led to the most modern technologies used today
in particle physics experiments, such as ATLAS and CMS at the Large Hadron Col-
lider (LHC) at CERN. These developments gave fundamental contributions to science
and, in the medical field, made possible innovative non-invasive imaging modalities
that allow exploring the human body, as it were transparent. I have personally
contributed to this adventure, first conceiving, constructing and testing high preci-
sion muon chambers for the ATLAS detector [14] and later designing, realizing and
operating the novel medical detectors discussed in Chapter 3.
Computed Tomography (CT) was first developed in 1972 [15] and it is based
on the use of X-ray beams passed through the patient’s body at different angles to
obtain cross-sectional images - the so-called slices - of the tissues being examined. By
putting together successive cross-sectional images, it is possible to obtain a precise
three-dimensional reconstruction of the morphology, which represents a fundamental
bit of information for studying and detecting a large variety of pathologies. For this
reason CT is today one of the most common diagnostic techniques and, in particular,
CT three-dimensional imaging is used as the basis for treatment planning in radiation
oncology.
The first full body Magnetic Resonance Imaging (MRI) scan was performed in
1977 [16] and, since then, this technique developed remarkably, also due to the ad-
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vances in the conception and realization of large superconducting magnets for ex-
periments in fundamental physics. MRI is based on the magnetic resonant effects
of protons immersed in a non-homogeneous magnetic field that is used to obtain a
spatial modulation of the characteristic response electromagnetic signal. With this
technique, high contrast and high resolution - of the order of 0.5 mm - images are
obtained. Since the resonance signal produced by protons is influenced not only by
their density in tissues but also by the magnetic properties of molecules located in
their proximity, MRI can be used to obtain information on the metabolism by means
of functional Magnetic Resonance Imaging (fMRI). MRI represents today a standard
in medical diagnostics and a very powerful research tool.
Positron Emission Tomography (PET) is one of the most important functional
imaging techniques. It based on the injection in the patient of specific β+ radio-
tracers. Thanks to the development and to the diffusion of compact cyclotrons, effi-
cient scanners based on novel scintillator detectors and specific radio-tracers, PET is
fundamental in several clinical and research applications, mainly in oncology, cardi-
ology and neurology. Following the pioneering studies performed in the fifties and in
the sixties, the first clinical PET apparatus was developed in 1975 [17]. Differently
with respect to SPECT - which makes use of gamma emitters such as 99mTc - PET is
based on the simultaneous detection of the two characteristic back-to-back 511 keV
annihilation photons. This technique allows for high accuracy of the order of 1 mm.
To give valuable clinical information, the up-take volumes of the radio-tracer have
often to be precisely correlated with their localization in the body. For this reason,
based on a PET scanner prototype developed in collaboration with CERN, the first
PET-CT scanner was constructed in 1998 [18]. Since then, a very fast diffusion fol-
lowed and PET-CT is nowadays standard in nuclear medicine. Along this line the
combination of PET with MRI is today a very active field of research.
The methods and the techniques I have here shortly summarized demonstrate the
continuous interplay between fundamental nuclear and particle physics and medical
applications. These developments are proceeding along several lines. Among them,
two represent the direct application of the most recent advances in particle accelerator
and detector physics: cancer hadrontherapy and artificially produced isotopes for
diagnostics and therapy. It is in these two fields where I have concentrated my
scientific efforts in the last years and, to set the basis for the material presented in
the following two chapters, they will be introduced here in more detail.
The most advanced application of particle accelerators to medicine is surely
represented by cancer hadrontherapy that was first proposed by Robert Wilson in
1946 [19], when powerful enough accelerators and accurate imaging techniques were
simply a dream. Former student of Ernst Lawrence, Wilson performed accurate
measurements of the range and of the energy deposition of 4 MeV protons in air
in 1941 [20] and observed that they deposit most of their energy near the end of
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their path - in what is now called the Bragg peak - as already observed by William
Henry Bragg with alpha particles in 1904 [21]. There was nothing unexpected about
this measurements but, when Wilson came in contact with John Lawrence and other
physicians, he had the idea of irradiating tumours by exploiting the properties of
the Bragg dose distribution produced by accelerated ions. Since then, a remarkable
scientific and technological development transformed Wilson’s vision into reality and
hadrontherapy can be considered nowadays an established clinical practice and a
challenging field of research in full evolution [22].
Cancer is one of the most diffused diseases and one person over three experi-
ences this pathology during life. Due to the progress of modern medicine, the overall
survival probability increased from less than 50% in the seventies to about 70%
in present times, reaching values higher than 95% for certain selected pathologies.
These encouraging results are mostly due to the improvement of scientific knowl-
edge as well as to the development and wide availability of effective diagnostic and
treatment modalities. About two-thirds of all cancer patients are treated using ion-
izing radiations, often in combination with other clinical options such as surgery or
chemotherapy. The above mentioned improvement in the survival probability is also
due to the advances of cancer radiation therapy towards the optimization of local
control.
In cancer radiation therapy, radiations are usually administered by teletherapy,
a modality in which beams produced outside the patient’s body are directed toward
the tumour volume. Brachytherapy is a less common clinical practice and is based on
radiation sources temporary inserted or permanently implanted inside the tumour.
In general, radiation therapy has curative purposes but it is important to stress the
role of palliative treatments, which have the aim of reducing the tumour volume and
to release the patient from pain.
With the aim of improving the local control, cancer radiation therapy is signed
by a profound evolution that, especially in the last twenty years, led to the intro-
duction of novel radiation sources, irradiation techniques and treatment planning
systems. The use of high-energy photon beams produced by 6-12 MeV linear ac-
celerators (linacs) progressively replaced 1 MeV photons emitted by intense 60Co
sources. In a clinical linac based system, accelerated electrons collide with a high
Z target where photons are produced by bremsstrahlung. To limit the effect of the
soft part of the spectrum and to obtain a flat distribution, lead flattering filters are
located after the target [23]. High-energy photons allow to better reach deep-seated
tumours, to increase the dose to the target and, consequently, to improve the tu-
mour control rate. It is important to stress the fact that the dose received during a
treatment by the so-called Organs at Risk (OAR) is of paramount importance and
represents the limiting factor in cancer radiation therapy. In order to selectively irra-
diate deep-seated tumours, multiple beams from several directions, usually pointing
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at the geometrical centre of the target, are used. This is achieved by employing a
mechanical structure containing the linac, which rotates around a horizontal axis
passing through the isocentre, the so-called isocentric gantry. The isocentre usually
coincides with the geometrical centre of the tumour target. The most recent Intensity
Modulated Radiation-Therapy (IMRT)[24] makes use of up to 10-12 photon beams,
often non-coplanar by means of a robotic couch for patient positioning and with the
intensity varied by means of a computer-controlled multi-leaf collimator. Further
developments allow for the continuous irradiation of the tumour while the gantry is
rotating. This is the case of Tomotherapy [25] or Rapid Arc [26] in which irradiation
with rotating modulated beams is performed in parallel with high-energy photon
imaging. All these techniques are based on sophisticated computer controlled treat-
ment planning systems which, based on CT imaging, allow determining the dose to
the target and to the surrounding healthy tissues together with the clinical beams to
be delivered to the patient. Furthermore, treatment planning systems and fraction-
ation schemes - which typically foresee treatments of 30-40 sessions of about 2 Gy
each - have been improved thanks to the recent developments in radiation biophysics.
As presented in Fig. 1.2, the absorbed dose due to a beam of MeV photons
is characterized by a roughly exponential decrease after an initial increase with a
maximum reached at a depth of 2-3 cm of soft tissue. The relative deep location
of the maximum is due to the relatively long range of the secondary electrons and
positrons released in the patient by photon interactions. This is the so-called build-
up effect, which gives the clinical advantage of a lower dose to the skin. On the other
hand, due to the exponential decrease, the dose is about one third of the maximum
at a depth of 25 cm. To treat deep-seated tumours, this fundamental fact leads to
an unavoidable dose to the surrounding healthy tissues and represents the major
limiting factor of photon beam radiation therapy for many clinical cases.
To overcome this limitation, hadrontherapy is based on a different kind of radi-
ation and can be considered the present frontier of cancer radiation therapy. The
basics, the developments and the perspectives of this discipline are discussed in de-
tail in several comprehensive collection of reviews (see for example [27]) and review
papers (see for example my publications [22] [28] [29]). In particular, carbon ion ther-
apy is treated in detail in Refs. [30] and [31]. Aiming at giving a concise overview,
only the basics aspects and facts are discussed here.
Based on the physical and radiobiological properties of accelerated ions, hadron-
therapy allows for higher precision treatments with respect to photons, as shown in
Fig. 1.2. Charged hadrons are characterized by a definite range in matter, which
is function of their initial energy, and by a relative low dose all along their path
sharply increasing only before the stopping point in the Bragg peak region. The
width and the relative height of the Bragg peak are particle dependent. As shown
in Fig. 1.2 (bottom), due to the larger energy straggling, protons are characterized
12
Figure 1.2: Dose distribution delivered by a single photon field and by a singe beam
of accelerated ions modulated in a Spread Out Bragg Peak (SOBP) (top). Dose
distributions are compared for protons produced by 21 MeV electrons and mono-
energetic beams of protons and carbon ions with the same range in water (bottom).
by a wider Bragg peak distribution with a consequent less sharp distal fall off with
respect to carbon ions. On the other hand, carbon ions undergo fragmentation due
to nuclear interactions occurring all along their path in matter. Since the fragments
have almost the same velocity as the primary ion, due to their smaller charge, they
are characterized by a longer range, responsible for the tail extending over the fall
off.
Either in the case of protons or of carbon ions, the Full Width Half Maximum
(FWHM) of the Bragg peak is of the order of a few millimetres, too small for treating
tumours having typical dimensions of a few centimetres. For this reason, several
Bragg peaks of different intensity and penetration depths are employed in a clinical
beam to obtain a homogeneous flat dose distribution corresponding to the target
13
Figure 1.3: The Spread Out Bragg Peak (SOBP) is a flat dose distribution obtained
by the superposition of several Bragg peaks corresponding to different energies and
intensities (top). The lateral penumbra for photons, protons and carbon ion clinical
beams is reported as a function of depth in water (bottom).
volume in the so-called Spread Out Bragg Peak (SOBP), as shown in Fig 1.3 (top).
Multiple scattering determines the lateral dose distribution of the clinical beam. As
presented in Fig 1.3 (bottom) [31] [32], protons and carbon ions are characterized by
a sharper lateral penumbra with respect to photons, especially at large depths. The
distal fall off and the lateral penumbra are usually defined as the distance between
points at 20% and 80% of the maximal dose and represent the two fundamental
properties used in treatment planning to protect the Organs At Risk (OAR), which
are often located in the proximity of the tumour.
During treatments, charged particle beams are administered by means of two
main methods: passive spreading and active scanning. The latter is very innovative
and allows for painting the tumour volume with unprecedented precision. In this
14
regard, due to their beam characteristics, linear accelerators can be very fruitfully
employed, as proposed in the papers reprinted in Chapter4. These two dose delivery
modalities will be compared and discussed in more detail in the next Chapter.
The penetration depth in tissues and the dose to be delivered directly determine
the main characteristics of the accelerator. In order to treat deep-seated tumours,
maximum depths of the order of 25 cm in soft tissues have to be reached. This directly
translates into the maximum energy of proton and carbon ion beams, which have
to be employed, typically 200 MeV and 4500 MeV (i.e. 375 MeV/u), respectively.
As far as beam currents are concerned, the limit is set by the amount of dose to
be delivered to the tissues, typically 2 Gy per litre per minute, as in the case of
conventional radiation therapy. This translates into beam currents on target of the
order of 1 nA and 0.1 nA for protons and carbon ions, respectively.
Living organisms are made of cells and the basic information of life is contained
in the DNA, which is the key element of cell reproduction. The size of a cell is in
the µm range while the diameter of the double helix of the DNA is about 2-3 nm.
Radiations produce damage to cells via ionization, a process that requires energies
of the order of 20-30 eV. These basic figures allow introducing the main parameter
used to quantify the effects of radiations on living bodies and to naturally determine
its scale. The Linear Energy Transfer (LET) in a medium is defined as dE/dl, where
dE is the amount of energy locally deposited when a length dl is traversed. A kind of
radiation capable to produce direct damage to the DNA must produce one or more
ionizations inside the double helix and has therefore to be characterized by a LET
of at least 10 eV/nm, i.e. 10 keV/µm. Below this value, radiations are defined as
low LET and produce damage to the DNA mostly indirectly, through the formation
of free radicals such as H2O
+ or OH− molecules (indirect action). These aggressive
ions are first formed from water, which constitutes 80% of a cell, and, successively,
migrate to damage the DNA. This is the case of X-rays, of MeV electrons produced
by photons used in radiation therapy and, to a large extent, of protons used in
proton therapy. On the other hand, high LET radiations are capable to produce
dense ionization columns, provoking direct damage to the DNA (direct action). This
is the case of high-energy ions to which astronauts are exposed or of accelerated
carbon ions used in cancer hadrontherapy. Due different cell damage mechanisms,
different biological effects correspond to different LET. To quantify this effect, the
Relative Biological Effectiveness (RBE) is introduced as the ratio between the dose
delivered by a standard radiation with respect to the dose from a test radiation
for a well defined biological effect, denominated end point. As standard radiation,
250 kVp X-rays are often considered.
The radio sensitivity of the tissues is influenced by the presence or absence of
oxygen, which plays an important role in the formation of free radicals. Especially
for low LET radiation, the presence of oxygen may lead to a large enhancement of
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the biological effects. This is expressed by the Oxygen Enhancement Ratio (OER),
which, for a given biological effect, is the ratio between the delivered dose without
and with oxygen. OER values up to 3 are observed for low LET radiation while,
being capable of provoking direct damage to the DNA, high LET radiations are
characterized by much lower values, usually near to one.
While protons have radiobiological characteristics similar to photons employed
in radiation therapy, carbon ions are characterized by a higher RBE and allow the
treatment of tumours, which are usually resistant to conventional radiation therapy
and proton therapy. Since the LET is not constant along the path of the ion in
matter, the RBE changes and reaches a maximum in the Bragg peak region. For
this reason, the SOBP for carbon ions has to be carefully modulated in order to
obtain a flat dose distribution by means of a non-flat physical dose distribution,
once the biological effects - i.e. the RBE - have been taken into account. This is
a very delicate issue and an actual theme of research. In clinical practice, several
treatment planning systems are available based on different models. Accelerated
ions having an intermediate mass between hydrogen and carbon are characterized
by an intermediate LET. They could represent promising clinical options for future
case-by-case personalized treatments.
From being practiced only in laboratories for nuclear and particle physics, of-
ten sharing beam time and resources with fundamental research, proton therapy
is becoming today a common clinical option in radiation oncology. About 100000
patients have been treated worldwide, about 40 hospital-based centres are treating
patients on a daily basis and about 20 are under construction or in an advanced
project phase [33]. On the other hand, carbon ion therapy is an active research
field, facing a challenging phase of intense scientific development and clinical tri-
als [30]. About 10000 patients have been treated with carbon ions so far, mostly
at the Heavy-Ion Medical Accelerator in Chiba (HIMAC) in Japan. In Europe, the
experience of GSI opened the way to the construction of other centres as the Hei-
delberger Ionenstrahl-Therapiezentrum (HIT) in Germany and the Centro Nazionale
per Adroterapia Oncologica (CNAO) in Italy [34].
As presented in Fig. 1.4, a modern hadrontherapy centre is based on a complex
facility in which the ion accelerator is connected to several treatment rooms by means
of beam transport lines. The particle accelerator is the heart of the system and
represents the only radiation source. For proton therapy, cyclotrons and synchrotrons
are used while for carbon ions only large (20 m diameter) synchrotrons are employed
at present. The treatment rooms are equipped with fixed beams - usually horizontal
but vertical and 45◦ are also in use - or with gantries. A gantry is a rotating structure
supporting the magnets for beam transport and the dose delivery system. In this
way, the patient can be irradiated from any direction, exactly like in conventional X-
ray radiation therapy. For proton therapy, a gantry is about 10 m high and 100000 kg
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Figure 1.4: Layout of the PROSCAN proton therapy centre at PSI. It features a
250 MeV superconducting cyclotron, two treatment rooms with rotating gantries,
one treatment room with a fixed horizontal beam for eye treatment (OPTIS 2) and
one room for research activities. The Energy Selection System (ESS) is present only
with cyclotrons and consists on a long magnetic channel, equipped with movable
absorbers and slits, needed to vary the beam energy. The Gantry 2 is optimized for
advanced spot scanning and is equipped with the SAMBA strip ionization chamber,
which is discussed in detail in Chapter 3.
heavy. For carbon ion therapy, only one isocentric gantry has been constructed so far
for the HIT centre, mainly devoted to clinical trials aimed at evaluating the need of
this kind of apparatus. This 600000 kg and 25 m long structure represents the limit
of the actual technology and new solutions are needed to improve the feasibility of
carbon ion gantries.
The tumour target is in general characterized by volume changes - usually shrink-
ages - during radiation therapy and some very common pathologies as lung cancer
are subject to movements of the order of 1 cm due to respiration. These effects are
at present usually neglected in the treatment planning and the development of tools
and techniques to take them into account and perform the necessary corrections rep-
resents an important research challenge. Along this line, Image Guided Radiation
Therapy (IGRT) aims at guiding the clinical beams on the basis of the on-line local-
ization of moving tumour targets and Intensity Modulated Proton Therapy (IMPT)
at fully exploiting the potentialities of the Bragg dose distribution by means of pencil
beams of variable intensity. In this framework, the dose distribution and the patient
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positioning systems are fundamental components. They are the focus of cutting-
edge multidisciplinary research in which particle accelerator and detector physics
play a crucial role. A sound example of these recent scientific developments is the
Gantry 2 [35] constructed for the PROSCAN project (Fig. 1.4) at the PSI. This new
device is designed to scan the tumour with parallel beams in a two-dimensional sur-
face and is able to rotate only by 180◦ to allow for an easier access to the patient and
for a more compact structure. The possibility to use X-rays parallel to the proton
beam and passing through a special aperture in the 90◦ magnet is foreseen to opti-
mize the treatment of moving organs. The monitoring of the scanned beams of the
Gantry 2 is realized by a high precision strip ionization chamber, which is discussed
in detail in Chapter 3.
In hadrontherapy the role of particle detectors is essential, not only to monitor
and measure the dose delivered to the patient. The accurate control of the beams
in the accelerator, at the extraction points and along the beam lines is crucial to
obtain an optimal and reliable treatment. For this reason, I dedicate part of my
scientific activity to the development of beam monitor detectors as the device based
on doped and optical silica fibres, discussed in Chapter 3. For an accurate treatment
planning, the precise knowledge of the range of the ions inside the patient body is
mandatory. In proton therapy, it is possible to obtain images of the patient using
high-energy pass-through protons, giving direct information on the density of the
traversed tissues. This technique is denominated proton radiography and represents
the focus of several research groups. It will be discussed in Chapter 3 together with
the novel method based on nuclear emulsion films, which was developed at LHEP in
Bern.
Treatment planning is at present based on CT but molecular imaging is expected
to play an important role in the near future [36]. In particular, the use of PET
radiotracers will allow the detection and the localization of hypoxic tumour tissues,
which are more resistant to radiation. This possibility opens the way to selective
treatments using different kinds of radiations as, for example, photons in combination
with carbon ions.
PET is both a medical and a research tool. Being able to provide specific and
very often unique information on important functions of living bodies, such as blood
perfusion, oxygen use, and glucose metabolism, it is employed more and more either
on humans or on animals. To exploit at best the large scientific potential of PET
imaging, the availability of a large variety of PET radioisotopes and radio-tracers
is crucial. A cyclotron laboratory for radioisotope production represents therefore
the fundamental instrument for an advanced clinical and research centre. In this
context, the SWAN [37] - which stands for SWiss hAdroNs - project was promoted
by the Inselspital and by the University of Bern. It aims at the establishment of
a multi-disciplinary clinical and research centre equipped with accelerators for PET
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Figure 1.5: The 18 MeV proton cyclotron installed at the Inselspital in Bern in the
framework of the SWAN project. One of the out-ports for radioisotope production
are visible together with the characteristic beam transfer line for research activities.
radioisotope production [38] and cancer hadrontherapy [39]. I am one of the initiators
of this project and, in particular, I have designed the new cyclotron laboratory
for radioisotope production and proposed its peculiar beam transfer line for multi-
disciplinary research activities (Fig. 1.5).
PET is a very vast discipline, which comprehends many aspects of physics, from
detectors and data acquisition systems for scanners to accelerators and detectors for
radioisotope production. Several recent reviews treat the argument of the production
of PET radioisotopes in detail (see for example Refs. [40] and [41]) and only a short
introduction to the main arguments related to my scientific activities are given here.
The main radioisotope used for PET imaging is 18F and the most common com-
pound is the 18-fluoro-deoxy-glucose (FDG). FDG is an analogue of glucose and
they are both transported into the cells in the same way. Once the cell membrane is
passed, they both undergo phosphorylation but, contrary with respect to phospho-
rylated glucose, phosphorylated FDG cannot be further metabolized and remains
trapped inside the cell [42]. Tumour cells use a large amount of glucose as energy
source and are therefore characterized by a large FDG uptake. FDG is used to in-
vestigate a large number of pathologies, cancer and brain diseases in particular, and
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at present accounts for the largest majority of PET examinations. The half-life of
18F is 110 minutes, allowing the transportation of FDG and other 18F based com-
pounds within a relatively large area around the production site. For these reasons,
a PET radioisotope production laboratory has to be necessarily optimized for 18F
production.
Other relevant PET isotopes are: 11C (20 min.), 13N (10 min.) and 15O (122 sec.).
These elements play a fundamental role in the mechanisms of life and are physiolog-
ically relevant. They have a considerable research potential and the possibility to
produce them is mandatory for a clinical and research facility. Being characterized
by much shorter half-lives with respect to 18F, they have necessarily to be used inside
the centre where they are produced.
PET isotopes are proton rich and are usually produced by bombarding a specific
target with proton beams. The use of deuterons is limited to a few specific cases [41].
For the production of 18F, a H2
18O enriched liquid target is used while for the other
above mentioned radioisotopes gas targets are also employed. Solid targets are less
common, as for the case of 64Cu production. For these reasons, a good production
centre must be equipped for all kind of targets. In particular, specific predispositions
have to be put in place for solid and gas targets to comply with the highest scientific
and radiation protection standards.
The accelerated beams must have sufficient energy to produce the desired nuclear
reactions and enough current is required to give good yields for the future use of
the produced radioisotopes. For these purposes, proton cyclotrons represent the
best solution due to the suitable energies, the large currents, the good quality and
stability of the beams, and the lower complexity and cost with respect to other types
of particle accelerators.
Nuclear reactions for the production of radioisotopes are governed by complex
mechanisms and several models have been developed. The compound nucleus model,
which was first proposed by Bohr in 1936 [43], can be used to derive the basic physical
quantities. According to this model, the accelerated particle and the target nucleus
form an intermediate state - the compound nucleus - which successively disintegrates
into the decay products. The compound nucleus forgets how it was formed, except
for the implications given by the fundamental conservation laws. In classical physics,
a charged particle induced nuclear reaction is possible only if the projectile of charge
z has energy larger than the Coulomb barrier
B =
zZe2
r
(1.1)
where Z is the atomic number of the target nucleus, e the charge of the electron and
r its nuclear radius. Due to quantum mechanics tunneling effects, lower energies are
possible. The Coulomb barrier sets the scale of the energies needed for radioisotope
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production. For the reaction
18O(p, n)18F (1.2)
the Coulomb barrier corresponds to 3.8 MeV and similar values can be obtained for
the production of the other above mentioned PET radioisotopes. Once the incident
particle has overcome the Coulomb barrier, there is another condition for a nuclear
reaction to take place since the available total energy must be larger than the total
mass of the decay products. Furthermore, the cross section for the reaction must be
large enough to obtain a good yield. For PET isotopes, the production cross sections
are characterized by several peaks in the 10-20 MeV region [41]. For these reasons,
PET cyclotrons operate in this energy range.
The beam currents used in radioisotope production are directly related to the
cross section and to the required amount of activity. They are limited by the amount
of power that the target can stand without being damaged. In the case of commer-
cial 18F liquid targets of the most common horizontal type, the beam current has to
be limited to about 75 µA. High power 18F liquid targets have been recently devel-
oped [44] [45], able to stand currents up to about 150 µA. However, due to cooling
limitations, the production yield is found to diminish above 100 µA. It has to be
remarked that high power may lead to the formation of impurities which may have
negative implications in the synthesis of the radio-tracers.
To estimate the produced activity, the decay during irradiation has to be taken
into account and saturation effects are relevant already for bombardment times of
the order one half-life. The production rate R, i.e. the number of nuclei formed per
second at a time t after the beginning of the irradiation, is given by
R =
dn
dt
=
ntI
e
(1− e−λt)
∫ Ef
Ei
σ(E)(
dE
dx
)dE (1.3)
where nt is the number of target nuclei per cm
3, I the beam current, λ the decay
constant of the produced radioisotope equal to ln 2
T1/2
, Ei and Ef the initial and final
energy of the incoming proton. At saturation, the production rate equals the decay
rate, and, assuming an average value for the cross section of 100 mb, one obtains the
value of 9 GBq/µA. This is the typical value for 18F production.
PET cyclotrons are usually able to produce activities of the order of 100-200 GBq
of 18F in 60-90 minutes of irradiation at 50-80 µA total beam current. After the syn-
thesis, this corresponds to about 50-100 GBq of FDG. As an example, this quantity
is enough for serving 2-4 PET centres examining about 10 patients each and located
at one hour distance from the production centre. The typical injected dose for one
examination is 400-500 MBq.
PET cyclotrons usually accelerate negative H− ions. The advantage with respect
to positive ion accelerators is represented by a much easier extraction by carbon foil
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stripping with efficiency close to 100%. Using two stripper foils and with an optimized
beam dynamics, it is possible to extract the beam into two different out ports at the
same time. This dual beam extraction allows for the simultaneous bombardment of
two targets. In this way, a larger production or the simultaneous production of two
different kind of radio-nuclides can be obtained. In the H− ion, the electrons are very
weakly bound, being the binding energy only 0.7 eV. For this reason, stripping may
occur during acceleration with consequent loss of beam intensity and production of
unwanted activation. To limit this effect, a good vacuum is crucial in this kind of
machines.
According to the survey performed by the IAEA in 2006 [46], 262 cyclotrons for
the production of isotopes are running in the 39 member states of the agency. The
real number is certainly higher and it is increasing continuously by approximately
50 units per year, mainly due to the installation of new PET radioisotope produc-
tion centers [47]. In the countries of the European Union, about 100 cyclotrons for
the production of radioisotopes are in operation. In particular, 33 are located in
Germany, 21 in Italy, 18 in France, and 4 in Switzerland [48] [49]. Besides medical
applications, cyclotrons for the production of isotopes represent the primary tool for
a wide range of biological, environmental and industrial research activities. Several
industrial solutions are available providing beams in the range 3-70 MeV [50]. As it
will be discussed in the next Chapter, industrial solutions have often to be adapted
and optimized for specific research needs.
PET radioisotope production facilities usually consist of a single cyclotron and a
single bunker. They are equipped with targets directly mounted on the accelerator
after the stripping foils. Since one or more production cycles per day are performed,
the beam area is practically not accessible for research activities due to radiation
protection hazards provoked by the high residual radioactivity. Since PET examina-
tions are performed in the morning or in the afternoon, production runs daily during
the night and early in the morning. This duty cycle leaves a considerable amount of
beam time available for other activities.
PET cyclotrons are characterized by a large research potential beyond PET ap-
plications. In particular, they can be optimized to produce beams ranging from frac-
tions of nA to several µA for novel detector, material science, radiation biophysics,
radiation protection, radiochemistry and radiopharamcy research activities [51]. To
exploit this potential without interfering with production, I proposed in 2007 the
realization of a specifically conceived beam transfer line and the construction of a
second bunker for the PET radioisotope production facility in Bern. This solution
represents a unique feature for a hospital-based centre. The new Bern cyclotron labo-
ratory (Fig. 1.5) was commissioned in 2012 and is now fully operational, as discussed
in the next Chapter.
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Chapter 2
Particle Accelerators for medical
Diagnostics and Therapy
This Chapter is focused on my contributions to particle accelerator physics applied
to cancer hadrontherapy and to the production of PET radioisotopes. Linacs are
fast cycling accelerators and their beam structure is optimal for beam scanning.
They are suitable to face the actual challenges of hadrontherapy. Cyclotrons are the
main instrument used for the production radioisotopes for PET imaging and, at the
same time, have a high potential for multi-disciplinary research. This concept is at
the basis of the new Bern cyclotron laboratory. Although very different, cyclotrons
and linacs can be combined to form a new kind of accelerator complex, the cyclinac.
Cyclinacs are proposed to perform radioisotope production and proton therapy with a
single apparatus and to realize an innovative linac based single-room proton therapy
facility. Applications to carbon ion therapy are also proposed. These issues are
discussed here in close connection with the publications reprinted in Chapter 4.
2.1 Linacs and Cyclinacs for Hadrontherapy
Hadrontherapy is nowadays facing a challenging phase aimed at improving the local
control of the tumours and at attacking cancers that cannot be treated with other
modalities [22] [27]. This is the case of radio-sensitive pathologies located very near
the OARs, of hypoxic tumours and of pediatric radiation oncology, where modest
doses to the healthy tissues may provoke heavy secondary effects and sequelae, in-
cluding radiation induced cancers. A special case is the treatment of moving organs
which is the focus of several recent developments. To reach these ambitious goals,
the superior physical and radiobiological properties of accelerated ions have to be
exploited at best and hadrontherapy has to be made available to the largest number
of patients. In this context, research in accelerator physics is essential to conceive,
study and eventually realize innovative solutions.
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Figure 2.1: Passive spreading is based on scatterers to widen and flatten the beam,
on a range shifter wheel (propeller) to obtain the SOBP and on personalized col-
limators and compensators to conform the dose distribution to the tumour volume
(top). Active scanning is based on the use of a pencil beam of variable intensity to
paint a slice of the tumour continuously or using successive spots. The irradiation of
successive slices results in a three-dimensional uniform dose distribution (bottom).
As mentioned in the previous Chapter, the SOBP can be obtained using two
main techniques: the most common passive spreading and the nowadays challenging
active scanning (Fig. 2.1). Passive spreading is relatively simple and requires the
construction of personalized collimators and compensators for every delivered radi-
ation field [52]. Extra doses are produced at the edges of the tumour, leading to a
non-optimal conformality. To reduce these effects, further approaches, still based on
passive devices, have been developed in Japan, as the layer stacking technique [53]
and the most recent cone type filter method [54]. Passive spreading does not make
use of a fundamental characteristic which distinguishes ions from photons: the elec-
tric charge. Based on this property, active scanning dose delivery systems have been
developed in the recent years. They are based on electromagnetically driven pencil
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beams without the need of any passive personalized device.
Two are the main active scanning techniques. The raster scanning has been
developed at the GSI Helmholtzzentrum fu¨r Schwerionenforschung [55] and is based
on a pencil beam of about 6 mm FWHM with variable intensity, which is moved
across the tumour to paint a slice at a fixed penetration depth. The beam energy is
then reduced in succession to cover the entire volume. Developed at the Paul Scherrer
Institut (PSI) [56], the spot scanning technique consists in chopping the beam from
a cyclotron using a fast kicker to obtain discrete dose spots of given energy, intensity
and direction which are used to obtain a uniform three-dimensional dose distribution.
More information on these two techniques can be found in Ref. [27]. It is important
to remark that active scanning allows for a much higher conformation of the dose and,
through IMPT, to cover complex concave tumor volumes with a minimal dose given
to the healthy tissues. Furthermore, much less neutrons and secondary particles are
produced with respect to passive spreading, leading to a significant reduction of the
corresponding unwanted dose. This new technique is surely superior but difficult to
implement, as demonstrated by the fact that only about 2% of the patients have
been treated with active scanning so far.
Among the many challenges of today’s hadrontherapy [22], a very fascinating
scientific theme is the treatment of organs which are affected by movements due to
respiration [57]. These movements are of the order of 10 mm with a frequency of
approximately 0.2 Hz. If not compensated, they may provoke remarkable under and
over dosages and spoil the high precision offered by hadrontherapy. The compensa-
tion can be obtained through three different approaches. The easiest one consists
on synchronizing the delivery of the dose with the patient expiration (respiratory
gating). This method is already employed in conventional radiotherapy but has the
draw back of an inefficient use of the beam time. The second and the third ap-
proaches are possible only with active scanning and can be combined. They are the
focus of several actual research developments. If the beam delivery is fast enough,
the tumor can be painted many times in three dimensions so that the movements of
the organs can cause acceptable dose variations within about 3% (multi-painting).
Furthermore, the movements of the organs can be detected and followed by means
of a suitable system. This information can be used as a feedback to adjust on-line
the transverse and longitudinal locations of the following spots (beam tracking).
To implement multi-painting and beam tracking, innovative solutions are needed
in many fields, including particle accelerator physics. An ideal beam would be char-
acterized by fast scanning capabilities together with fast changes of the energy. In
hadrontherapy, cyclotrons and synchrotrons are nowadays in use. The beam pro-
duced by cyclotrons is characterized by a fixed energy and by a 30-100 MHz pulsed
beam which can be considered continuous when compared with the human respira-
tion period. To vary the energy of the clinical beam, mechanically moving absorbers
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Accelerator Is the beam Is the output energy Which is the time
always available? variable? to vary Eclin (ms)?
Cyclotron Yes No 100
Synchrotron No Yes 1000
Linac Yes Yes 2-5
Table 2.1: Proprieties of the beam of various accelerators relevant for hadrontherapy.
Eclin is the energy of the clinical beam reaching the patient.
are used in the long and complex Energy Selection System (Fig. 1.4). With this de-
vice, the energy can be varied in about 100 ms. The beam produced by synchrotrons
is characterized by a spill time of about 1 s, during which the beam is extracted
for therapy, and by a filling and accelerating time of about 1-1.5 seconds in which
the beam is not available. The energy can be varied from spill to spill. The beam
periodicity is similar to the one of the respiration cycle, which generally represents
a disadvantage for the irradiation of moving organs.
An innovative solution is represented by fast cycling high frequency linear acceler-
ators. Compared to presently operated cyclotrons and synchrotrons (Table 2.1), they
can provide pulsed beams with an optimal repetition rate, intensity and energy mod-
ulation for applications in hadrontherapy. Along this line, fast cycling synchrotrons
have also been recently proposed [58].
On the basis of the high potential of linacs for hadrontherapy, the TERA Foun-
dation - of which I was the Technical Director from 2003 to 2006 - initiated and still
pursues an intense research program to which I have strongly contributed [59] [60].
Among the many research activities in which I was involved, the conception and the
design of an innovative linac based proton therapy facilitiy - denominated Institute
for advanced Diagnostics and RAdiation therapy (IDRA) - is discussed here in more
detail.
Several are the problems to assess for the realization of a linac that will be suitable
for an hospital-based proton therapy facility optimized for beam scanning. Besides
the very stringent requirements on the beam characteristics, the accelerator must be
compact, reliable and consume a reasonable amount of power. To realize a compact
linac, a high average electric accelerating field is needed. For proton therapy, energies
up to about 200 MeV have to be reached, implying average accelerating fields of at
least of 10 MV/m to limit the length of the accelerator to 20 m. Since the shunt
impedance increases with the frequency as Z ∼ f 1/2, the choice of a high frequency
allows for higher electric accelerating fields for the same power consumption. For
this reason, the frequency of 3 GHz was chosen, although unusual for proton linacs
since it implies several design difficulties. In particular, small resonant cavities have
to be realized with the implication of a small iris for the beam. For proton therapy,
this does not represent a serious problem since, as already observed in the previous
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Figure 2.2: Design of a half accelerating CCL cavity of a high frequency linac. The
red curves represent the electric field lines of the accelerating mode. The arrows
indicate the regions where the Pointing vector S and the electric and magnetic fields
(E, H) are maximal, in the so called nose.
Chapter, currents of the order of 1 nA or less are needed. High accelerating fields
imply a very accurate design of the accelerating cavities, especially in the so called
nose region where discharges have to be avoided. On the other hand, the choice of
3 GHz gives the advantage of the availability of standard klystrons to provide the
needed radio-frequency (RF) power. The design of a typical high frequency cavity is
shown in Fig. 2.2.
For enhancing the compactness and for obtaining a larger shunt impedance, the
Coupled-Cavity Linac (CCL) - sometimes also referred as Side Coupled Linac (SCL) -
structure working in the pi/2 mode was chosen. The structure of the accelerator and
the first prototype [59] [61] are shown in Fig. 2.3. This standing wave accelerator
has a biperiodic structure composed by on-axis accelerating cells (AC) and off-axis
coupling cells (CC). The CCs are located off-axis to reduce the length of the linac
and have the fundamental role to allow the RF power to be distributed to all the
accelerating cavities. In the pi/2 mode, the electric field follows the scheme [1, 0,
-1, 0, 1, 0, . . .] so that a proton must transit from an AC to the next in a time
equal to T/2, where T is the RF period. For this reason, the distance d between two
successive accelerating cells has to be
d =
vT
2
=
βλ
2
(2.1)
where v is the average velocity of the protons and λ the wavelength of the RF. Being
the RF fixed, this implies that the distance between successive ACs must change
along the linac and becomes larger at higher energies. For the first prototype, d is
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Figure 2.3: Mechanical design of the four tanks of the LInac BOoster (LIBO)
prototype, forming one unit made of two modules. Each tank is made of a number
of basic elements machined with high accuracy in copper and called half-cell-plates.
Permanent Magnetic Quadrupoles (PMQ) are located between two successive tanks
to assure focussing by means of a FODO lattice (top). The first LIBO prototype
after it was cut out to examine the brazing procedure. The CCL structure formed
by accelerating (AC) and coupling (CC) cells is visible (bottom).
2.8 cm at 200 MeV (β = 0.57) and 1.7 cm at 60 MeV (β = 0.34). For constructive
reasons, it is not possible to vary d from cell to cell and the linac is organized in tanks
in which d is kept constant. Four tanks constitute an accelerating unit fed by one
single klystron coupled via a bridge coupler (Fig. 2.3). The copper structure of the
accelerator is made of half-cells brazed together. Due to the mechanical construction
difficulties and to the fact that the shunt impedance decreases with β, the first proof
of principle prototype was realized starting from 62 MeV. This prototype successfully
accelerated protons and, during power tests, reached an accelerating gradient of
28.5 MV/m, much larger than the design value of 15.8 MV/m [61].
The choice of 62 MeV was also due to the fact that this is the typical energy
of cyclotrons used for the treatment of ocular uveal melanomas and that the linac
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could be used as a booster to treat deep seated tumours. The combination of a
cyclotron and a linac has been denominated cyclinac. Following the success of the
first prototype, a second more challenging one was designed and built starting from
30 MeV [59].
CCL structures become highly inefficient at low β due the low shunt impedance
and they have to be coupled to another kind of accelerating structure as, for exam-
ple, a Drift Tube Linac (DTL) preceded by a Radio Frequency Quadrupole (RFQ).
Moreover, at very low β, d becomes very short and the mechanical structure im-
possible to realize and tune to the right frequency. The tuning of the cavities is
performed by successive measurements aimed at finding the optimum configuration
of the cell by successive machining and changes in the length of specific copper rods
(tuners). With this procedure, a precision of 1/1000 at 3 GHz can be obtained. After
a careful study based on simulations and calculations, the starting energy of 30 MeV
- corresponding to β = 0.25 and d = 1.25 cm - was considered the optimum.
There is another important reason to choose 30 MeV as the starting energy of
the linac. Considering the fact that the proposed linac is designed for medical appli-
cations, an unusual and novel solution was proposed by the TERA Foundation: the
use of a 30 MeV high current cyclotron for radioisotope production as the injector.
This idea led to a further development of cyclinacs. This new combination allows
the production of radioisotopes for diagnostics (PET and SPECT) and for radioim-
munotherapy by means of the cyclotron in parallel with advanced scanning proton
beam teletherapy by means of the linac used as a booster.
As discussed in the previous Chapter, cyclotrons for the production of PET iso-
topes are characterized by energies ranging from 10 to 20 MeV, too low to be used as
the injector of a CCL linac. 30 MeV cyclotrons are more complex and less common
machines. Nevertheless, they are commercially available and are usually devoted to
the production of SPECT isotopes, 123I and 201Tl in particular. They are able to
extract the beam at different energies and they can produce very large currents, up
to 500 µA or more. For these reasons, they have also a large research potential, an
interesting feature for an academic clinical environment. These machines can also
be used for the production of PET isotopes.
IDRA is shown in Fig. 2.4. Its name was chosen since in medieval latin the
name Idra (Hydra in English) designated a mythologic creature with many very vital
heads [62], just as the high-current cyclotron in the proposed facility.
The design of IDRA demanded to assess several specific issues which were never
studied before: the cyclotron-linac coupling, the linac structure starting from 30 MeV
and the realization of a beam optimized for the treatment of moving organs by
means of spot scanning. In particular, the energy variation and the multi-painting
capabilities had to be carefully studied. Moreover, the possibility to treat ocular
pathologies with beams of 62-65 MeV had also to be possible.
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Figure 2.4: The layout of the Institute for advanced Diagnostics and RAdiation
therapy (IDRA) features a 30 MeV cyclotron, a linac of the LIBO type and three
treatment rooms equipped with rotating gantries and a fixed beam line for the treat-
ment of eye tumours.
Since the linac is a pulsed accelerator with a duty cycle of about 10−4, its ac-
ceptance is definitely not appropriate for the almost continuous beam produced by
the cyclotron used as an injector. To avoid the large unwanted irradiation during
the down-time of the linac and all the consequent radiation protection issues, the
ion source of the cyclotron has to be pulsed to match the RF structure of the linac.
Furthermore, during proton therapy runs, the intensity of the ion source has to be
changed from spot to spot to obtain at least a course variation of the intensity of the
beam injected in the linac. 30 MeV cyclotrons have an external ion source on which
specific pulsed electronics can be installed. The einzel electrostatic lenses located
in the Low Energy Beam Transfer line (LEBT) can also be used to obtain further
variations of the intensity of the beam injected into the cyclotron. To improve the
matching and increase the precision of the intensity variation, a fast kicker and a fast
quadrupole doublet located at the injection of the linac can be employed. Simula-
tions and calculations showed that an overall precision in the beam intensity within
5% could be obtained with a variation in the number of protons per pulse N of
Nm/200 < N < Nm, where Nm corresponds to the maximum current of the clinical
beam.
The design and the optimization of the linac were focussed on the main figures
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Accelerated particles protons
Type of linac CCL
RF Frequency [MHz] 2998.5
Input energy [MeV] 30
Output energy [MeV] 230
Total length of the linac [m] 18.5
Cells per tank / tanks per module 16/2
Number of accelerating modules 20
Thickness of a half cells in a tank [mm] 6.3-14.6
Diameter of the beam hole [mm] 7.0
Normalized transversal acceptance [mm mrad] 1.8 pi
Number of Permanent Magnetic Quadrupoles 41
Length of each PMQ [mm] 30
PMQ gradients [T/m] 130-153
Synchronous phase [deg] -15
Peak power per module (with 20% losses) [MW] 3.0
Effective shunt impedance ZT2 (inj.-extr.) [MΩ/m] 30-90
Axial electric field (inj.-extr.) [MV/m] 15-17
Number of klystrons (peak power=7.5 MW) 10
Total peak RF power for all the klystrons [MW] 60
Klystron RF efficiency 0.42
Repetition rate [Hz] ≤200
Duration of a proton pulse [µs] 1.5
Max. number of protons in 1.5 µs (2 Gy l−1 min−1) 4× 107
Effective duration of each RF pulse [µs] 3.2
RF duty cycle 3.2× 10−4
Plug power at 100 Hz + 100 kW auxiliaries [kW] 150
Table 2.2: The main parameters of the linac specifically designed for IDRA.
of merit [59]: the effective shunt impedance, the quality factor Q0, the field unifor-
mity and the power efficiency. Transverse and longitudinal beam optics were also
optimized by means of specific solutions. The main parameters of the linac of IDRA
are reported in Table 2.2.
The linac is composed of 20 accelerating modules. Calculations show that the
effective shunt impedance is roughly proportional to the length of each module and
varies from 30 MΩ/m for the first to 90 MΩ/m for the last one. This fact allows
to inject almost the same power in all the modules with minimal variations of the
accelerating electric field Ez, which varies from 15 to 17 MV/m. In this way, a com-
pact linac of 18.5 m length is obtained. The relative small value of the synchronous
phase of -15◦ strongly reduces defocussing effects due to RF but limits the phase
acceptance. This is not a problem since low currents (nA) are needed for therapy
and large currents (more than 100 µA) can be provided by the cyclotron.
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The transverse beam optics [63] is realized by 41 Permanent Magnet Quadrupole
(PMQ) magnets and requires some care since the output energy of the linac has to
be varied and a beam of 65 MeV has to be extracted for eye therapy, as shown in
Fig. 2.4. The use of PMQs is an elegant and simple solution with the draw back of
the impossibility to adjust the optics of the FODO according to the beam energy.
To maximize the acceptance in a so wide range of conditions, a large betatron phase
advance per focussing period is appropriate. On the other hand, a low value allows
for a higher focalization. Since the beam emittance decreases with βγ along the
accelerator, the betatron phase advance σt is varied from 74
◦ at the injection to 44◦
at the end of the linac. The gradient of the PMQs is varied from 130 to 153 T/m,
accordingly. This solution minimizes the losses and allows the transport of a beam
of 65 MeV through the full linac.
Multiparticle simulations [63] showed that the linac acts like a filter and only
a negligible fraction of the beam (always less then 7%) is not fully accelerated.
Moreover, the fraction of the injected beam that is not fully accelerated has an energy
much lower then the fully accelerated beam and can be therefore easily separated
by means of the dipole magnets generally used to guide the beam to the treatment
rooms. The energy spread of the accelerated beam is very small, about 0.45 MeV.
Particular care has been devoted to the design of the ACs, especially in the nose
region [59] [64]. In a standing wave cavity, the ratio between the maximum field on
the surface of the cell and the accelerating field in the gap has to be kept under control
to avoid discharges. According to calculations and measurements on prototypes, this
ratio can be varied in the range 5-8 allowing for accelerating fields of 30 MV/m at
3 GHz. This gives a safe margin of operation to the linac.
Another important issue that pertains to CCL structures operating in the pi/2
mode is the stop band. For the linac of IDRA, it was studied by means of a model
based on a circuit representation of coupled electric RC oscillators [59] [64]. ACs
and CCs resonate at the frequencies ωa and ωc, respectively, when considered alone.
When N cells are coupled, they form a system of N coupled oscillators. This sys-
tem is characterized by N different oscillation modes ω1, ω2, . . . , ωN , one for each
phase difference between two neighbor cells φ1, φ2, . . . , φN . The ω versus φ curve is
denominated the dispersion curve of the structure. If N approaches to infinite, the
dispersion curve shows a discontinuity for φ = pi/2 and the frequencies
ωa√
1− ka
≤ ω ≤ ωc√
1− kc
(2.2)
do not allow to excite the structure. Here, ka and kc are the AC-AC and CC-CC
coupling constants, respectively. This phenomenon is called the stop band. To
achieve a stable pi/2 mode configuration, the stop band has to be closed by choosing
the coupling constants in such a way that the upper and lower frequency of the stop
band coincide. When the stop band is closed, the slope of the dispersion curve in
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Figure 2.5: Beam structure of the linac of IDRA. It allows for multi painting and
beam tracking by means of a high repetition rate, variable intensity and fast energy
variation from spot to spot.
the proximity of the pi/2 mode is found to be proportional to the AC-CC coupling
constant. It is therefore important to keep this parameter large in order to separate
at maximum the pi/2 mode from the neighboring modes. In the case of the linac of
IDRA, the stop band was reduced down to 1 MHz which is better than the overall
required precision of 1/1000 on 3 GHz. With the chosen configuration, the pi/2 mode
can be excited safely and with high precision.
The linac of IDRA is able to produce a beam with the structure reported in
Fig. 2.5. The beam is composed by 1.5 µs long discrete spots of variable intensity
from Nm to Nm/200 with the repetition rate of 200 Hz, where Nm is the maximum
number of protons per pulse. Higher repetition rates and longer spots are possible but
imply a larger power consumption. Nm is calculated to be able to deliver 2 Gy l
−1s−1,
the typical dose delivery rate in particle therapy. The factor 200 has been chosen
to allow for a precision in the delivery of the dose in the SOBP well below 2.5%,
typical value required in radiation therapy. During the 5 ms between two successive
spots, the energy of the beam is varied by switching off a certain number of modules
starting from the last one and the transverse position changed by means of scanning
magnets (Fig 2.1). The energy variation and the corresponding positions of the
Bragg peaks are shown in Fig. 2.6. Due to these unique features, linacs represent an
innovative and advanced tool for beam scanning, multi-painting and beam tracking
for the treatment of moving organs.
In the proposed linac, the energy can be in principle varied spot-by-spot between
the cyclotron output (30 MeV) and the maximum value (230 MeV). In practice,
this is not the case either for clinical reasons or for the finite momentum acceptance
of the beam transfer line located downstream of the linac. For the treatment of
moving organs, variations in the proton range of ±10 mm are needed and the typical
momentum acceptance of the transfer line within ±1.5% is enough for the case of
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Figure 2.6: Proton depth dose distribution when the number of the active accelerat-
ing modules is varied one by one. To avoid super-positions a different normalization
is used for each curve.
deep seated tumors. To study this effect more quantitatively, a fit on experimental
data leads to the formula
R = 0.00176 (E[MeV])1.82 cm (2.3)
where R is the proton range and E the kinetic energy. This implies that
∆R
R
= 1.82
∆E
E
(2.4)
and, considering that the protons are almost non-relativistc,
∆R
R
= 3.64
∆p
p
(2.5)
where p is the momentum. Variations of ±10 mm are well within the momentum
acceptance for 175 MeV protons, which correspond to a penetration depth of 20 cm.
For tumours located at a depth of 10 cm, 120 MeV are needed and variations only up
to ±5.5 mm are possible. To enhance the range variation, a 10 cm absorber located
very close to the patient could be used together with larger beam energies.
To obtain a continuous energy variation, two different methods were considered
and studied [63] [59], both acting only on the last active module: the variation of the
peak power and the change of the phase with respect to the rest of the linac. Both
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Figure 2.7: Number of protons (in arbitrary units) delivered in each voxel of the
central transversal slice needed to obtain a 1.25% uniform dose distribution inside
a 6.2 cm radius spherical volume (1 liter) centered at 20 cm depth in water (left).
Number of visits needed to obtain a flat equivalent dose distribution with the con-
dition that any missing visit does not change the total local dose by more than 3%
(right). The coordinates z and x are given as a number of voxels, z is the longitudinal
and x the transversal coordinate.
the solutions can be implemented by acting on the low-level phase circuits of the RF
driver and provoke an increase in the energy spread. This effect has to be carefully
assessed since an increase of the energy spread directly translates into an increase
of the uncertainty of the range, according to Equation 2.4. As stated above, the
intrinsic energy spread of the linac is about 0.45 MeV with a negligible dependence
on the total energy if modules are completely on or off, as shown in Fig. 2.6. When
a continuous energy variation is performed, simulations show that the energy spread
increases up to 0.6 MeV in case of the variation of the peak power in the last active
module. The increase is up to 0.9 MeV by changing the phase of the last active
module. For this reason, the first method was preferred. It has to be noted that
an energy spread of 0.6 MeV produces a range variation of 1.4 mm and 1.1 mm
at 200 MeV and 150 MeV, respectively. This effect is acceptable since it has to be
compared to the natural straggling of 4.3 mm and 2.3 mm at 200 MeV and 150 MeV,
respectively.
To asses the distribution of the dose, to evaluate the effects of the errors and
the time needed for a treatment with spot scanning and multi painting, a study was
performed by considering the irradiation of a spherical tumor of one liter, centered
200 mm deep in water [59] [60]. For this study, one direction for the irradiation
was considered. At 200 mm water depth, the lateral spread of the Bragg peak due
to multiple scattering has a FWHM of 11.5 mm which gives an overall FWHM of
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Figure 2.8: Number of carbon ions (in arbitrary units) delivered in each voxel of the
central transversal slice needed to obtain a 1.25% uniform biological dose distribution
inside a 6.2 cm radius spherical volume (1 liter) centered at 20 cm depth in water
(left). Number of visits needed to obtain a flat dose distribution with the condition
that any missing visit does not change the dose by more than 3% (right). The
coordinates z and x are given as a number of voxels, z is the longitudinal and x the
transversal coordinate. With respect to protons, due to the smaller FWHM of the
beam, the number of spots for each dimension is double.
13.5 mm when combined with a proton pencil beam having a FWHM of 7 mm. This
corresponds to a 6.4 mm 80%-20% lateral fall-off. Following the same specifications
used for spot scanning at PSI [56], the distance between the spots has been chosen
to be 75% of the FWHM. The results are reported in Fig. 2.7. The proximal voxels
need many less visits to obtain the SOBP with respect to the distal ones that are
visited 12 times. In this way, each spot is painted 3.5 times in average so that about
5200 spots in total are needed. For the calculations, the condition that a missing
spot produces an error on the local dose of less than 3% was imposed. At 200 Hz, a
tumor of one liter can be repainted 12 times in less then 30 seconds, when the dead
times due the lowering of the magnetic fields in the delivery magnets are taken into
account [65]. The maximum number of protons in one voxel is needed only for the
distal spots and corresponds to Nm=4 × 107, which is well feasible considering the
high current provided by the cyclotron. When an organ is painted 12 times with
spots containing a number of protons which fluctuate from one visit to the next by
±5%, a ±1.5% effect on the dose accuracy is induced. This result has to be compared
with the ±2.5% uniformity of the dose required in radiation therapy.
Cyclinacs are proposed also for carbon ion therapy [59] [60]. At present only syn-
chrotrons are employed for the running centers and for the current clinical projects.
Due to their large cost and complexity, innovative alternative solutions are under
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study. One possibility is represented by superconducting cyclotrons, which are nev-
ertheless big and complex. Compact superconducting cyclotrons with a beam energy
limited to 300 MeV/u corresponding to 17 cm depth in water, are also proposed. This
kind of accelerator allows for the treatment of a relatively large but limited spec-
trum of pathologies. For example, it has been estimated that 85% of all head and
neck cancers could be treated. In this context, a linac able to boost the energy to
400 MeV/u would be beneficial to eliminate any limitation due to the penetration
depth. For this purpose, a specific linac was studied by TERA. This kind of acceler-
ator is similar with respect to the linac of IDRA but presents specific problems to be
addressed. In particular, a new kind of ion source is needed to provide the necessary
beam current which can compensate the losses due to the cyclotron-linac coupling.
The distribution of the dose needs also a particular care since the Bragg peak pro-
duced by carbon ions penetrating at 200 mm (330 MeV/u) is about 3.1 mm, 4 times
sharper with respect to protons having the same penetration depth. Furthermore,
the RBE of carbon ions changes with the penetration depth and a non uniform dis-
tribution of the physical dose has to be implemented. Considering the energy spread
due to the linac, a pencil beam with 5.9 mm FWHM, corresponding to a fall-off of
2.8 mm, was considered. The value of the fall-off is longitudinally too narrow but
the unique features of this kind of linac allow for producing the necessary spread by
slightly varying the energy in different visits of the same voxel. The results of this
study are reported in Fig. 2.8. With respect to protons, a much larger number of
spots is needed to cover the same spherical volume, about 80000. This implies the
need of a larger repetition rate. At 400 Hz, about 220 seconds are needed to perform
a dose delivery with a 12 visit repainting leading to effects of less then ±1.5% on
the dose accuracy [65]. A high repetition rate and a high gradient are fundamental
features for a carbon ion linac for therapy. Along this line, a high frequency linac at
5.7 GHz was studied [60]. On this basis, the first RF cavities were constructed and
tested [66].
High gradient linacs are beneficial also for proton therapy. As pointed out in
Ref. [22], the number of treatment rooms needed for photon, proton and carbon ion
therapy scales as 82, 8 and 1, respectively. For proton therapy, the need is estimated
to be about 7 treatment rooms for 10 millions inhabitants and several medium sized
hospitals are starting to consider proton therapy nowadays. For these reasons, single-
room proton therapy facilities are the focus of intense research and development
programs. Along this line and on the basis of the experience gained with the design
of IDRA, a linac based single-room proton therapy facility was proposed and patented
by TERA [67] [59]. This system is shown in Fig. 2.9. This apparatus consists of a
cyclotron used as the injector of a system composed by two high-frequency and high-
gradient linacs mounted on a rotating structure. The active dose delivery system
is based on the apparatus designed for IDRA and, due to the rotation around the
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Figure 2.9: TULIP (Turning LInac for Prototherapy) is a linac-based single-room
proton therapy facility optimized for fast cycling spot scanning. The version pre-
sented here is based on two 5.7 GHz high gradient linacs connected by a buncher.
The dose is delivered by scanning by means of two transverse magnetic fields to an
area equal to 20×20 cm2.
patient, it is similar to a helical Tomotherapy. Since protons are used instead of
photons, this system has the advantage of a much better sparing of the healthy
tissues surrounding the tumour target. This innovative instrument presents many
challenges, such as the mechanical structure, the beam transport through different
accelerating structures and the distribution of the radio-frequency (RF) power to the
rotating linacs.
Another application of cyclinacs was recently proposed by TERA and PSI [68].
The superconducting cyclotron installed at PSI is designed for the treatment of deep
seated tumors and produces 250 MeV protons (Fig. 1.4). A linac booster could en-
hance the energy of the protons to 350 MeV and will open the way to new treatment
modalities. The shoot-through technique is based on the sharpness of the lateral
penumbra of high energy protons which do not stop in the patient’s body. This
modality is an actual theme of clinical research, especially for the treatment of inter-
cranial pathologies. Furthermore, higher energy beams passing through the patient’s
body can be fruitfully employed for proton radiography, an important imaging tech-
nique that will be discussed in the next Chapter.
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Figure 2.10: The Bern cyclotron opened during commissioning. The 30◦ dees
are visible together with the magnetic poles producing the alternating magnetic
field for vertical focussing (hills and valleys). The two flaps for the D− operation
mode and some of the eight exit ports are also visible together with the targets for
18F production. The exit port number four is connected to the BTL whose first
quadrupole doublet is located in the cyclotron bunker.
2.2 The new Bern Cyclotron Laboratory and its
Research Beam Line
The Bern cyclotron laboratory [69] is situated in the campus of the Inselspital and
represents the first phase of the SWAN project [37]. This new facility has been
conceived to fulfill two main goals. The first one is the production of PET radio
tracers for the Inselspital and for other healthcare institutions by means of the most
modern industrial Good Manufacturing Practice (GMP) technologies. As observed in
the first Chapter, PET cyclotrons are characterized by a high potential for research.
The second goal is to perform cutting-edge multidisciplinary scientific activities in
parallel with radioisotope production.
I have been involved in this project since the very beginning, being in charge
of the choice of the accelerator, of radiation protection as Radiation Protection Of-
ficer (RPO) and of the conception of the research facility [38]. Besides scientific
programs based of the the produced radioisotopes, valuable developments on accel-
erator physics, novel particle detectors, radiation protection, radiation biophysics
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Constructor Ion Beam Applications (IBA), Belgium
Type Cyclone 18/18 HC
Accelerated particles H− (D− on option)
Energy 18 MeV (9 MeV for D−)
Maximum current 150 µA (40 µA for D−)
Number of sectors 4
Angle of the dees 30◦
Magnetic field 1.9 T on the hills and 0.35 T on the valleys
Radio frequency 42 MHz
Weight 24000 kg
Dimensions 2 m diameter, 2.2 m height
Ion sources 2 internal PIG H−
Extraction ports 8 (one of which connected with the BTL)
Extraction Carbon foil stripping (for single or dual beam)
Strippers Two per extraction port on a rotating carrousel
Isotope production targets 4 18F−, 15O (11C and solid target are foreseen)
Beam Transport Line (BTL) 6.5 m long;
two quadrupole doublets (one in each bunker);
XY steering magnet; upstream collimator;
2 beam viewers; neutron shutter
Table 2.3: Main characteristics of the Bern cyclotron and its beam transport line.
and materials science can be performed [51] only if a regular access to the beam area
is possible. Furthermore, beams of variable shape and intensity must be available.
Considering the severe access limitations due to radiation protection in radioisotope
production machines and the fact that suitable research beams cannot be produced
only with the cyclotron, I proposed in 2007 the construction of an external Beam
Transport Line (BTL) terminated in a second bunker. Although more complex and
unusual for a hospital-based facility, this solution allows performing production and
research independently and efficiently by means of a fully dedicated apparatus.
The beam line vault is connected via underground pipes to a physics laboratory
situated on the same floor. Specific pipes have been installed also for the passage
of highly radioactive solid targets without the need of opening the bunker doors.
A dedicated radiochemistry and radiopharmacy laboratory is situated on the floor
above the cyclotron [70] [71] together with the GMP production plant. Radioisotopes
produced in any of the targets of the cyclotron can be transferred to any of the hot
cells located in the upper floor by means of shielded capillaries.
After a phase of study and design, the construction started in 2010. In June 2011,
the civil engineering infrastructure was ready and the cyclotron was successfully
rigged inside its bunker, after having passed a series of functional tests performed
at the factory. Following the construction and test of all the service subsystems,
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the installation of the cyclotron and of the beam line proceeded on schedule and
the first proton beams were accelerated and extracted in February 2012. An intense
optimization phase followed and, at the end of 2012, the whole facility was fully
operational.
The heart of the facility consists of the IBA Cyclone 18 MeV cyclotron shown
in Fig. 2.10. The main technical data are reported in Table 2.3. The cyclotron is
equipped with two H− ion sources, a redundancy aimed at maximizing the efficiency
for daily medical radioisotope production. It provides large beam currents up to
150 µA in single or dual beam mode. Extraction is obtained by stripping the negative
ions by means of 5 µm thick pyrolytic carbon foils. In dual beam mode, the beam is
extracted by two strippers located approximately at an angular distance of 180◦. The
relative position of the last orbit can be tuned in such a way that different currents
can be extracted in the two out ports. Although difficult to obtain, this feature was
required for the Bern cyclotron in order to operate two different targets producing
two different kind of radioisotopes. It is important to remark that high current
negative ion cyclotrons are possible thanks to the development of specific materials
for the strippers, able to stand temperatures of about 1500 ◦C or more produced by
the energy released by the protons and, mainly, by the stripped electrons.
An optimized vertical focussing and longitudinal phase stability are crucial for
high current cyclotrons. This is realized by alternating four 60◦ sectors at high
magnetic field (hills) with four 30◦ sectors at low magnetic field (valleys). This
implies that the orbits are not circular and that a complex and iterative mapping
procedure is necessary to obtain a precise magnetic filed. It has to be noted that a fine
tuning of the cyclotron can be performed only on site by measuring the accelerated
beam. In particular, the magnetic field of the Bern cyclotron was carefully regulated
in the central region to obtain the optimum transmission of the low energy ions
produced by the ion source. An iterative procedure was applied aimed at modifying
the gap of the magnet in the central region (shimming).
The average magnetic field of 1.4 T gives the cyclotron frequency
νc =
qB
2pim
(2.6)
of 21 MHz. Since this cyclotron is equipped with two dees, only RF frequencies
which are even harmonics of the cyclotron frequency lead to acceleration. As shown
in Table 2.3, the RF frequency of 42 MHz corresponds to the second harmonic for
H− ions. This kind of cyclotron is able to accelerate also deuteron beams, as tested
at the factory. In the case of D− ions, the cyclotron frequency is about one half and,
being the RF fixed, the machine works in the fourth harmonic. To correct for effects
due to the mass defect of deuterons, perturbations to the magnetic field are produced
by specific movable components inserted in the upper part two of the valleys (flaps),
as shown in Fig. 2.10.
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Figure 2.11: The BTL is terminated in the beam line vault where a neutron shutter
is located before the second quadrupole doublet. A beam viewer and a four finger
collimator allow to position the beam before its use for scientific purposes.
Acceleration occurs when the ions cross the borders of the dees and the energy
gain per turn Ek is given by the formula
∆Ek = VdeeNq sin
(
hα
2
)
(2.7)
where Vdee is the RF peak voltage, N the number of accelerating gaps corresponding
to twice the number of the dees, q the charge of the accelerated ion, h the harmonic
mode and α the azimuthal dee angular length. With a RF peak voltage of 30 kV,
this leads to values of Ek of 60 keV and 100 keV for H
− and D−, respectively. In this
way, H− ions reach the extraction energy of 18 MeV after 300 turns while 9 MeV D−
are extracted after 90 turns.
The performances obtained with the Bern cyclotron for radioisotope production
are excellent. In particular, 500 GBq of 18F can be produced with dual beam irradi-
ations lasting less than 70 minutes. Considering the total efficiency of the chemical
synthesis (usually about 60%), this corresponds to about 250 GBq of FDG produced
in a single run. This result has to be compared with the typical figures given in the
first Chapter. It has to be noted that with this apparatus larger productions would
be possible and that 500 GBq represents the legal radiation protection limit for a
laboratory of this kind (type B) in Switzerland.
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Figure 2.12: Schematic view of the BTL of the Bern cyclotron laboratory, in which
all the main elements are highlighted.
Beam lines are quite rare for 18 MeV cyclotrons. They are usually only about 2 m
long, located in the same bunker as the cyclotron and dedicated to the bombardment
of solid targets. This kind of apparatus was not suitable for our purposes. At the
beginning of the SWAN project, IBA was designing a 6 m long beam line, aimed at
the production of radioisotopes by means of high current beams, of the order of 50 µA
or more. For the aims of the Bern project, I proposed the construction of a BTL
able to transport the maximum current of 150 µA with more than 95% transmission.
High transmission is crucial to limit unwanted activation and to protect scientific
equipment sensitive to radiation. Furthermore, this performance is important for
future developments since remarkable progress is made on targets able to stand very
large currents. At the same time, currents down to fractions of nA are needed
for research purposes. Furthermore, beams of different sizes ranging from a few
millimeters to a few centimeters diameter on target have to be obtained. To fulfill
these ambitious goals, specific solutions were implemented and the initial industrial
design modified. These original developments are described here in more detail [72].
The BTL is shown in Figs. 1.5, 2.10 and 2.11 and a schematic view is presented in
Fig. 2.12. The FODO lattice of the BTL is realizeded by two horizontal-vertical (H-
V) quadrupole doublets, the former located in the cyclotron bunker and the latter
in the BTL one. An unavoidable design constraint is represented by the distance
between the two quadrupole doublets due to the 180 cm thick wall separating the
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Figure 2.13: Simulation of the beam envelope in the XZ plane in the original
industrial design of the BTL. The beam is centered on the first viewer and has a tilt
angle of 7 mrad with respect to the optical axis. The XY steering magnet - located
in front of the first quadrupole doublet - is able to perform a substantial correction.
However, distortion effects still remain, leading to a non optimal transmission. The
horizontal (H) and vertical (V) focusing quadrupoles are indicated.
two bunkers. This thickness is due to radiation protection since large fast neutron
fluxes are generated during isotope production, for example via (p,n) reactions. For
the same reason, a movable cylindrical neutron shutter is located inside the beam
pipe when the BTL is not in use. In this way, the penetration of neutrons to the
second bunker through the beam pipe is minimized. Taking into account the space
needed for the vacuum pumps, beam diagnostics, collimators and other devices, the
beam line is 6.5 m long.
Since the trajectory of the ions is curved inside the cyclotron and straight in
the beam line, the injection of the beam into the BTL is critical, especially if a
transmission larger of 95% is required. To study this issue, simulation studies were
performed with Beamline Simulator [72] [73]. It has to be noted that the transfer
of the extracted beam is much more difficult in the accelerating (horizontal) plane
as compared to the vertical plane. The simulations showed that the beam has to
be centered with respect to the BTL better than 1 mm and, at the same time, its
parallelism with respect to the axis has to be better than 1 mrad to ensure high
transmission. In the case of larger deviations, the beam is subject to an overly large
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Figure 2.14: Simulation of the beam envelope with the modified design of the BTL.
The beam is extracted from the cyclotron in the same conditions as in Fig. 2.13. With
the XY steering magnet located as near as possible with respect to the cyclotron, it
is possible to obtain a centered and parallel beam with negligible distortion effects
and an optimized transmission.
dipolar field when passing through the quadrupoles and the beam envelope becomes
highly distorted.
To obtain a centered beam, the accuracy of the mechanical alignment of all the
elements of the BTL is crucial. This was realized by means of a laser installed inside
the cyclotron to reproduce the ideal beam path and to give a precise reference for
the positioning of the two quadrupole doublets. To allow for corrections of the beam
direction after the extraction, a XY steering magnet able to bend the 18 MeV beam
of maximum ±7 mrad vertically or horizontally is used. In the initial design, this
magnet was located in front of the first quadrupole doublet, about 1.5 m away with
respect to the extraction point. Measurements of the beam profile performed with
gafchromic film detectors showed that the beam exited the cyclotron with an angle of
7 mrad when centered on the first beam viewer. As demonstrated by measurements
and by the simulation reported in Fig. 2.13, these conditions led to the non optimal
transmission of about 80%, well below the required 95%. These measurements were
performed using standard carrousels for the strippers and with an optimized azimuth
angle of the strippers aimed at directing the beam right in the centre of the steering
magnet. The XY steering magnet had to be set at its maximum current to correct
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Figure 2.15: The beam spot extracted from the cyclotron is measured by the first
beam viewer located before entering the FODO lattice (a). By adjusting the optics
of the beam line, the beam spot on target can be adjusted according to the specific
needs. Beam spots of about 1 cm (b) and 3 mm (c) diameter are reported here, as
measured with the beam viewer located after the FODO lattice.
for the exit angle.
To improve the transmission, the position of the XY steering magnet can be
optimized by locating it as close as possible with respect to the extraction point,
as shown in Fig. 2.14. This modification was implemented and the transmission
improved significantly to more than 90%. Also in this case, the XY steering magnet
had to be set at its maximum current, a situation which did not allow for further
improvements with a standard set-up.
Another parameter can be used to tune the centering of the beam in the hori-
zontal plane: the radial position of the stripper. Together with the azimuth angle,
it determines the position and the angle with which the beam leaves the cyclotron.
Once the radial position of the stripper is fixed, the azimuth angle can be adjusted
to find the optimal exit angle.
Variations of the radial position of the stripper induce changes on the output
energy of the beam. As it was already observed, orbits are characterized by successive
increases of 60 keV with the RF voltage set at 30 kV. Since the radius ρ depends on
the kinetic energy E as
ρ =
√
2Em
qB
(2.8)
a radial increase of the position of the stripper of 1 mm corresponds to an increase
of the extracted energy of about 60 keV. Furthermore, since extraction is performed
on the hills of the magnet, changes in the radial position of the stripper determine
changes in the path length inside the region where the magnetic field is maximal.
These two effects lead to a high sensitivity of the angle with which the beam leaves
the cyclotron with respect to the radial position of the stripper. These effects are
difficult to simulate, mainly due to the stray field of the cyclotron magnet.
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Figure 2.16: Measurement of air contamination on the main exhaust of the facility
due to three successive irradiations with 18 MeV protons extracted into air at an
intensity of about 50 nA for 60 seconds. The peaks correspond to 10, 13 and 15 MBq,
respectively, mostly due to 11C produced by the reaction 14N (p, α) 11C with a
contribution of about 10% of 13N from the reaction 16O (p, α) 13N.
For the IBA 18 MeV cyclotron, the strippers are mounted on a rotating carrousel
with a fixed radial position. Thus only the azimuth angle is adjustable, once the
dimensions of the carrousels are chosen. To determine the optimal radial position
of the stripper for an optimum injection in the BTL, several carrousels with dif-
ferent radii were constructed and beam profile measurements were performed using
gafchromic film detectors. The optimum was found at a radius 5 mm larger than the
standard one. With this modification together with the new position of the steering
magnet, excellent results were obtained. A transmission larger than 97% was mea-
sured at the maximum current of 150 µA. Below 10 µA, the transmission was found
to be about 100%. A transmission of 99% was obtained when operating in dual beam
with a total summed current of 150 µA. In this mode, only a part of the beam is
extracted towards the BTL and the beam emittance is consequently smaller. Beams
of different shapes can be obtained at the end of the BTL ranging from a few mm
to a few cm, as shown in Fig. 2.15. It has to be noted that all these measurements
were obtained with a negligible current on the XY steering magnet, demonstrating
the optimum centering of the beam.
In a complex installation where very high quantities of radioactive substances are
produced, radiation protection is essential. The Radiation Protection Monitoring
System (RPMS) of the Bern cyclotron is composed of about 50 sensors and is both
a safety and a research tool. Ambient dose gamma radiation levels, air contamina-
tion, and neutron fluxes are continuously monitored on-line and can be accurately
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studied. Special attention has been devoted to the monitoring of the emission of
radioactive gases into the atmosphere by means of sophisticated sensors able to de-
tect air contamination levels down to 10 Bq/m3, as shown in Fig. 2.16 [74]. Along
this line, novel compact sensors for the measurement air contamination are under
development in Bern [75] using both gas and solid state sensors.
The commissioning and the optimization of the cyclotron and of the BTL were
successful, either for production or for multi-disciplinary research activities. This
process clearly put in evidence the important role of beam monitoring devices. Along
this line, the first research activities focus on the development of innovative beam
monitor detectors, as presented in more detail in the next Chapter. Furthermore,
this enterprise is fostering research in accelerator physics in Bern [76] [77] [78].
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Chapter 3
Particle Detectors for medical
Applications of Ion Beams
This Chapter is focused on my contributions to particle detectors used for the mea-
surement and the control of ion beams in medical applications. The main feature
of hadrontherapy is its precision. The control of the beams during treatments and
the knowledge of the range of the ions are fundamental for an optimum treatment.
Especially for active beam scanning, segmented ionization chambers represent a valu-
able solution for on-line monitoring. Proton radiography is a powerful technique to
assess the range of the accelerated ions and innovative solutions are under study
for its application in a clinical environment. Beam monitoring along transport lines
or in front of the target is fundamental for all applications, cancer hadrontherapy
and radioisotope production in particular. These issues are discussed here in close
connection with the publications reprinted in Chapter 5.
3.1 Segmented Ionization Chambers for BeamMon-
itoring in Hadrontherapy
The on-line measurement of the intensity, the position and the shape of the clinical
beam just before entering the patient’s body is of paramount importance in hadron-
therapy treatments. This information is used to monitor the amount and the spatial
distribution of the delivered dose. In the case of active scanning and moving organs,
these measurements can be used to apply corrections during the irradiation by means
of an appropriate feedback system.
In parallel with the development of accelerators for medical applications, I dedi-
cate part of my scientific activity to novel particle detectors. During the time I was
with the TERA Foundation, I contributed to the design, the construction and the
test of segmented ionization chambers for the on-line monitoring of therapeutic ion
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beams. This activity continued after I moved to the University of Bern. Two detec-
tors are discussed in detail in this paragraph: a pixel and a strip ionization chamber,
named MATRIX [79] and SAMBA [80] [81], respectively. The Strip Accurate Mon-
itor for Beam Applications (SAMBA) detector was developed for the Gantry 2 at
PSI where it is currently in use, as shown in Fig. 1.4.
To measure the integral of the dose, parallel plate ionization chambers are usually
used. For passive scattering, the flatness of the clinical field is generally controlled
by means of ionization chambers subdivided in four or five sectors. In case of active
scanning, the position of the pencil beam is normally monitored using wire chambers
located in front of the patient and covering the whole clinical field, typically about
20 × 20 cm2.
An innovative alternative is represented by highly segmented pixel or strip ioniza-
tion chambers, able to provide spatial information and to measure the fluence at the
same time. If the electrodes are made very thin, scattering effects can be minimized
with respect to standard systems. Due to the absence of multiplication, the signals
produced by the low intensity therapeutical beams have to be collected and treated
by a dedicated sensitive electronics and read-out system. This problem is enhanced
by the fact that each strip or pixel sensor necessarily detects only a fraction of the
ionization signal produced inside the fiducial volume of the detector.
To better describe this problematic, let’s consider the proton therapy beam of
the PSI. The dose is delivered by spots of variable temporal length depending on the
amount of dose to be delivered. The intensity can be varied from 0.2 to 2 nA. A
typical situation is represented by an average current of 0.2 nA with spots of 5 ms,
corresponding to a total of about 6×106 protons per spot. In a ionization chamber
with a gap d between the two electrodes, the gain factor G represents the average
number of electron-ion pairs produced by one single proton traversing the chamber.
The gain factor is given by
G =
dE
dx
d
W
(3.1)
where W is work function, the average energy to produce an electron-ion pair. For
dry air W is 35 eV. Considering a planar ionization chamber operating in air with d
of 1 cm and a beam energy of 160 MeV, the total charge of 150 pC is produced by
each spot. Due to the segmentation of the detector, charges down to 10 pC have to
be measurable with a good precision.
For the read-out of segmented ionization chambers, the TERA Foundation and
the Italian National Institute for Nuclear Physics (INFN) in Turin developed a spe-
cific very large scale of integration (VLSI) chip, named TERA 06. This device has
64 independent channels based on a recycling integrator architecture. Each channel
is equipped with a 16-bit digital counter and is connected to one strip or pixel of the
detector. The collected charge is continuously integrated by a capacitor of 0.6 pF.
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Figure 3.1: Schematic view of the MATRIX pixel ionization chamber.
When the voltage of the capacitor is larger than a programmable threshold value, the
capacitor is discharged by the injection of pre-defined quanta of charge. In this way,
the collected charge is measured by counting the quanta of charge needed to bring
back the voltage of capacitor under threshold. The use of recycling integrators allow
reducing dead time effects to a negligible level. The sensitivity of the measurement
can be adjusted by varying the quantum of charge in the range between 100 and
800 fC. The maximum read-out frequency of 5 MHz limits the maximum current of
each channel to 4 µA. For this chip, the linearity of the measurement of the charge
was measured to be better than 1% in the full range of operation and the noise to
be the less than one count per channel per second. The tested minimum read-out
time for one channel was of 1 µs.
The data acquisition systems of MATRIX and SAMBA [82] are based on specif-
ically designed TERA 06 boards, each hosting two TERA 06 chips and capable to
handle 128 channels in total. For the measurements presented here, the maximum
sensitivity of 100 fC was chosen for the quantum of charge, which corresponds to 100
counts for a total collected charge of 10 pC.
The structure of MATRIX is shown in Fig. 3.1 and is based on five successive
fibreglass frames. The external ones are equipped with glued mylar foils which allow
to maintain the planarity of the internal cathodic and anodic electrodes in case
a gas is used at non atmospheric pressure. The sensitive volume of the detector
corresponds to the air gap between the anode and the cathode foils. This gap can
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Figure 3.2: The segmented anode with the 1024 pixels and the guard ring (left).
The MATRIX chamber fully assembled. The fibreglass frame and the eight TERA 06
electronic boards for the read-out are visible (right).
be easily changed by substituting the spacer. A gap of 5 mm was chosen, which for
a bias voltage of 400 V gives an electric field of 800 V/cm in the sensitive volume.
The gap and the applied electric field determine the collection time of the electrons
and of the ions. The drift velocity v is given by
v = µ

p
(3.2)
where µ is the charge mobility,  the electric field and p the pressure of the gas
filling the sensitive volume. The mobility in air is of the order of 10−4 m2atm/Vs
for ions and about 1000 times smaller for electrons. In this way, collection times of
the order of 1 ms and 1 µs are obtained for ions and electrons, respectively. Since
these detectors are based on the measurement of the negative charge collected by
the segmented anodes, the timing characteristics are well suitable for spot scanning
where the duration of a spot is of the order of a few milliseconds.
The anode and cathode foils are glued to the respective frames by means of a
specific procedure able to guarantee a good planarity. MATRIX has a sensitive area
of 21 × 21 cm2 subdivided in 32 × 32 pixels of 6.5 × 6.5 mm2. The 1024 pixels are
read-out by 8 TERA 06 boards. The anodic electrode was manufactured at CERN
using techniques derived from the construction of printed circuit boards (PCB). In
order to minimize the amount of material traversed by the beam, the electrode is
made of a thin 50 µm kapton foil, with a deposition of 17 µm copper on each side.
Aluminium depositions are at present under study to allow for a even lower amount
of material. In the case of hadrontherapy, simulations show that negligible effects
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Figure 3.3: MATRIX installed in a gantry room of the Loma Linda University
Medical Center (left). Measurement of the two-dimensional dose distribution for a
field shaped for the treatment of a prostate cancer. The two dimensions are measured
in number of pixels (right).
are produced to the beam as far as the dose distribution is concerned using both
copper or aluminium. To minimize noise effects, the sensitive area of the anode is
surrounded by a guard ring kept at the same potential as the pixels. The other side
of the anode foil contains the pixel-pad connections used to transport the signals to
the read-out electronics. The anode and the fully assembled MATRIX detector are
shown in Fig. 3.2.
Tests of the detector were first performed by X-ray irradiation in order to verify
the correct operation of all the pixels and of the corresponding read-out chains.
Following the successful beam tests at the 40 MeV cyclotron of the Joint Research
Centre of the European Commission in Ispra (Italy), MATRIX was tested with
passive scattering clinical beams at the Loma Linda University Medical Center in
California, as shown in Fig. 3.3.
In Loma Linda, the measurement campaign [79] was focused on the monitoring of
several two-dimensional maps of clinical fields (Fig. 3.3 (right)) and on the pixel-by-
pixel inter-calibtation procedure. The Bragg peak produced by a 149 MeV proton
beam was measured by interposing successive layers of water equivalent absorbers
between the nozzle and the chamber. The range in water was estimated to be 154 mm
in good agreement with the simulation and with previous measurements performed
in Loma Linda. The effects of the exit window of the accelerator and of the material
of the propeller present in the nozzle were taken into account. The total counts of the
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Figure 3.4: Schematic view of the SAMBA detector composed of two orthogonal
strip ionization chambers.
chamber were measured also with additional 10 mm water equivalent material with
respect to the Bragg peak position. In this way, the effect of the dose produced by
neutron induced recoil protons can be put in evidence. A clear signal was observed
and the total counts were estimated to be about 0.1% of the maximum corresponding
to the Bragg peak, in agreement with previously performed measurements with the
same beam and with data reported in Ref. [83]. The read-out speed of 2 ms for
the full chamber was reached, an essential feature for its use with active scanning
systems.
The Gantry 2 at PSI was conceived for double parallel magnetic beam scanning
over an area of 20 × 12 cm2 with spots of 8 mm FWHM and a beam intensity ranging
from 0.2 to 2 nA. The temporal length of one spot and the temporal distance between
successive spots are both of the order of a few milliseconds. For this dose distribution
technique, the precise and fast determination of the position of each spot represents
the most important information that an on-line monitoring detector has to provide.
To accomplish this task, a strip ionization chamber is surely more appropriate with
respect to a pixel detector since the lower number of channels to be read-out allows
for a higher detection speed. Furthermore, strips can be made smaller with respect
to pixels giving a higher resolution on the determination of the centroid of the spot.
Using two orthogonal strip chambers, the positions and the projections of all the
delivered spots can be measured and stored. If needed, the two dimensional map
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Figure 3.5: The SAMBA detector under test at the Gantry 1 at PSI. The magnetic
sweep of the beam is detected by the 128 strips of the U chamber while the 88
channels of the T chamber are sensitive to the movements of the table.
of the clinical beam can be reconstructed at a later stage, since negligible shape
variations are expected between different spots.
The SAMBA detector was designed for the on-line monitoring of the Gantry 2
and was conceived, built and tested in the framework of a collaboration between
the TERA Foundation and the PSI. It consists of two strip ionization chambers, as
shown in Fig. 3.4.
SAMBA is composed by two chambers (denominated T and U, according to the
denomination used for the Gantry 2) with the anodes segmented with 2 mm strips.
The two chambers are orthogonal one with respect to the other and cover a sensitive
area of 25.6 × 17.6 cm2. The chamber U and T have 128 and 88 strips, respectively.
This is due to the choice of having the same strip width, and therefore the same
spatial resolution, for the two chambers. Each chamber is read-out by one TERA 06
board [82]. For the board corresponding to the T chamber, 40 channels are not
connected to any strip and can be used to monitor the noise in the TERA 06 chip.
The two chambers operate in air and, to increase the gain with respect to MATRIX,
a gap of 10 mm was chosen. The fibreglass frames and the anodes are manufactured
with the same technology used for MATRIX. To minimize the amount of material
traversed by the beam, a single two-sided aluminized cathode is located in the middle
of the two sensitive volumes. The two anodes are connected to the ground potential.
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Figure 3.6: Successive spots (top) and zoom on a single spot (bottom) detected by
the SAMBA detector. The measurements of the total charge performed by the T and
U chambers (white and red, respectively) overlap within the statistical fluctuations.
The time interval between full read-out procedures of the two chambers is set to
120 µs.
A bias voltage of -800 V is applied to the cathode to obtain an electric field of
800 V/cm used to collect the charge produced by ionization.
For the beam tests of the SAMBA detector, the Gantry 1 at PSI was used, as
shown in Fig. 3.5. This apparatus is able to sweep the beam magnetically only in
one direction and two dimensional spot scanning is realized by combing the magnetic
sweep with the mechanical movements of the patient’s table. The beam energy was
set to 160 MeV.
Several measurements were performed to test the timing and dose response of
SAMBA. One of those is reported in Fig. 3.6, where a series of 9 spots of a duration
of 5 ms and with a temporal separation of 5 ms was directed towards the centre of
the detector. The average current in the flat top of the spots was set to 0.2 nA.
The signal due to the spots is well visible over a negligible background. The total
intensity presented in Fig. 3.6 is measured as the sum of all the counts in the U
and in the T chambers, respectively. The results of the two chambers are consistent
within the statistical fluctuations. The average value of the flat top is found to be 37
counts (3700 fC) for temporal distance between two successive read-out procedures
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Figure 3.7: One single spot produces a signal on several strips and is well modeled by
a gaussian curve (top). A flat linear dose distribution is obtained by superimposing
33 spots spatially separated by 5 mm in the U direction. The movement of the beam
is obtained using the fast sweeping magnet (bottom).
of the two chambers of 120 µs. Once the gain is taken into account, the average
current was measured to be 0.20±0.03 nA, in good agreement with the set-up value
of 0.2 nA. The obtained total read-out time of 120 µs is suitable for spot scanning.
This value can be reduced to about 25 µs using a specific fast data acquisition (DAQ)
system.
Single spots are measured by examining the signal in the strips, as reported in
Fig. 3.7 (top). The shape of the projection of the spots can be fitted with a gaussian
function either for the T or for the U chamber. As normal for a particle beam, the
distribution of the collected charge presents a slight excess on the tails with respect
to the fitted gaussian. The position of the centroid of the spots can be determined
with a precision better than 0.1 mm. For the FWHM values ranging from 8 to 10 mm
were measured with a precision better than 0.1 mm. Either for the position or for the
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Figure 3.8: The T and U positions of the spots corresponding to the flat linear
dose distribution of Fig. 3.7 (bottom) are measured by fitting the projections (left).
The T and U positions of the spots corresponding to a 10 × 10 cm2 flat square
dose distribution. The 441 spots are separated by 5 mm either in the T or in the U
direction (right).
FWHM, the error is dominated by the beam characteristics and not by the intrinsic
precision of the detector.
Using the sweeping magnet, series of spots producing lines in the U direction
were measured, as reported in Fig. 3.7 (bottom). Here 33 spots separated by 5 mm
were used to produce a 16 cm long flat dose distribution. The difference between
the measurements of the total collected charge performed by the two chambers was
measured to be less then 1%. The reproducibility of the measurement was estimated
to be better then 0.4% by repeating the full procedure five times. The modest and
repetitive up and down behavior between adjacent channels is due to a slight different
gain of the amplifiers located on different sides of the TERA 06 chip, as shown in
Fig. 3.7 (bottom). This effect is of the order of 1%. Once a calibration procedure
was applied, the flatness of the dose distribution was measured to be better than
0.6%, well within the therapeutic requirement of 2.5%.
The T and U positions of the centroids of all the spots composing the flat linear
dose distribution of Fig. 3.7 (bottom) were measured by performing gaussian fits.
The results are shown in Fig. 3.8 (left). The measurement shows a good linearity.
A modest deviation of about 2 mm with respect to the table in the T direction
was determined. This effect was known and due to a modest misalignment of the
90◦ magnet of the gantry with respect to the table. Furthermore, 250 µm deviations
from the linearity were observed at the edges due to non-linearities of the 90◦ magnet.
Although with a worse precision, these effects were known since the commissioning
of the Gantry 1. It has to be remarked that these small effects have a negligible
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Figure 3.9: Measurement of the standard deviation of all the spots in the T (left)
and U (right) directions for the flat linear dose distribution of Fig. 3.7 (bottom).
clinical impact.
By using both the magnetic and the mechanical movement of the table, square
flat distributions were measured, as reported in Fig. 3.8 (right). Here 21 × 21 spots
at a nominal distance of 5 mm in the T and in the U directions form a square of
10 × 10 cm2. To evaluate the precision on the positioning of the 441 spots with
respect to a given grid, the minimum of the residual function
R =
∑
i
(T fiti − T gridi )2 +
∑
j
(U fitj − U gridj )2 (3.3)
was searched for, where T fiti and U
fit
j were measured by fitting the data and T
grid
i
and U gridj were calculated on the basis of the model chosen for the grid. To describe
the grid, the spot-to-spot distances ∆T and ∆U and the tilt angle due to the 90◦
magnet were left as free parameters. By means of this procedure, the best grid was
found to have 4.94 mm and 4.95 mm for ∆T and ∆U , respectively, very close to the
nominal values of 5 mm. The two-dimensional mean distance between the measured
positions and the corresponding points on the grid was determined to be 90 µm.
It has to be noted that these values are remarkably precise if compared with the
precision on the alignment of the patient which is of the order of one millimeter.
The SAMBA detector allows to precisely monitor the shape of the spots on-line.
As shown in Fig. 3.9, the standard deviation of the spots was measured for the
flat linear dose distribution of Fig. 3.7 (bottom). These measurements show a clear
increase of the width in the T direction of about 20% from the first to the last spot
while a decrease of the same amount was observed in the U direction. These results
clearly put in evidence the rotation of the ellipse representing the two-dimensional
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projection of the beam spot in the U-T plane due to dynamic effects induced in the
beam when passing through the magnetic field of the 90◦ bending magnet.
To evaluate the linearity of SAMBA in the measurement of the delivered dose,
a comparison was performed with respect to the standard system used to assess
the dose in the Gantry 1. With this apparatus, the dose is measured in terms of
Monitoring Units (MU) by means of a planar ionization chamber located upstream.
A MU corresponds to about 7000 protons. A series of spots of increasing temporal
length, and therefore of increasing dose, was measured. The total counts of the two
chambers were compared with the dose given in terms of MUs. The results for one
of the chambers are reported in Fig. 3.10 (top). A very good linearity was found,
demonstrating the capability of SAMBA to measure the delivered dose.
Following this result, the Bragg peak distribution of a 138 MeV pencil beam was
measured by interposing the water equivalent PMMA layers of the range shifter of the
Gantry 1. Each layer corresponds to 2 mm of water. The data for the two chambers
are reported in Fig. 3.10 (bottom). For the range in water, the value of 133 mm was
measured in good agreement with the simulation and with measurements performed
with other methods. The Bragg distribution is compared in Fig. 3.10 (bottom) with
the reference data daily used at PSI for the Quality Control (QC) procedures. A
good agreement is found and one can conclude that SAMBA represents a powerful
instrument for QC procedures in proton therapy.
Using SAMBA, a much faster QC procedure can be implemented. It has to be
noted that the standard procedure implies the use of a ionization chamber dosimeter
operating inside a water phantom that has to be installed and then removed in the
treatment room before the beginning of the treatments. Measurements are taken at
different depths by means of a quite time consuming procedure. On the other hand,
SAMBA is able to measure the reference Bragg peak distribution in less than one
minute and does not require the installation of any supplementary equipment.
Effects due to charge recombination were also studied by changing the current
upstream of the Gantry 1. Spots with total flat top currents of 0.2, 0.4 and 0.6 nA
were measured. For the same amount of MUs, i.e. for the same amount of protons
traversing the detector, the total counts measured by SAMBA were found to decrease
of 0.3% and 0.6% for 0.4 and 0.6 nA, respectively, when compared to the standard
intensity of 0.2 nA. From these measurements one can conclude that the effects due
to charge recombination are negligible, once the flat top current is set and only
the modest usual fluctuations of the beam intensity occur during proton therapy
treatments.
The development and the tests of the MATRIX and SAMBA detectors demon-
strate that pixel and strip segmented ionization chambers, alone or in combination,
can be fruitfully used for the control of the clinical beams in hadrontherapy facilities,
especially in the case of active beam scanning dose distribution systems.
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Figure 3.10: The total counts measured by SAMBA show a good linearity with
respect to the Monitoring Units (MU) used to measure the delivered dose at PSI
(top). The Bragg depth dose distributions measured by SAMBA is compared with
the reference data used for the Quality Control (QC) at PSI (bottom).
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3.2 Proton Radiography with nuclear Emulsion
Films
The clinical advantage of hadrontherapy relies on the possibility of modulating the
range of the impinging ions to conform the dose distribution to the target volume
with a higher precision with respect to X-rays. This implies that the uncertainty
in the assessment of the ion range inside the patient’s body is crucial for an opti-
mum treatment, either for passive scattering or for active scanning dose distribution
systems.
X-ray Computed Tomography (CT) is presently used to provide the necessary
information to the Treatment Planning System (TPS) for the calculation of the dose
distributions. Since the Hounsfield Units (HU) are obtained from X-ray attenuation,
a calibration curve has to be used to determine proton or carbon ion ranges, which
depend on the density of the traversed material. This procedure can introduce range
uncertainties up to 5% and limits the advantages produced by the ballistic properties
of charged ions in matter.
To overcome this limitation, high-energy protons passing through the patient’s
body can be used to obtain medical images. By means of a mono-energetic proton
beam, the measurement of the residual range gives direct information on the average
density of the traversed material. This method is more sensitive to density differences
with respect to X-ray imaging, especially for soft tissues. This technique is denom-
inated proton radiography and can be used for a precise assessment of the range
inside the patient’s body with uncertainties below 1%. Furthermore, the dose given
to the patient can be significantly reduced with respect to ordinary X-ray radiog-
raphy, since every single proton passing through the patient’s body brings valuable
information.
Proton radiography was proposed in 1968 [84] as an imaging technique. Only a
few years later images of very high contrast were obtained and density differences of
0.5% were reconstructed with good accuracy. Images taken from several directions
can be combined, leading to a full three-dimensional reconstruction of the density by
means of Proton Computed Tomography (PCT), as first proposed in 1976 [85]. De-
spite the good contrast, the spatial resolution is severely limited by multiple Coulomb
scattering and energy straggling. Due to the limited spatial resolution and since large
accelerators are needed to produce high-energy beams, proton radiography and PCT
were almost abandoned after the first pioneering studies in favour of other imaging
techniques, as CT or MRI.
The recent development of hadrontherapy determined a renewed interest on pro-
ton radiography and PCT. Several techniques are nowadays the focus of intense
research programs aiming at developing reliable and compact systems to be used
in a clinical environment. As already remarked [68], some proton therapy centers
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Figure 3.11: Principle of proton radiography with nuclear emulsion film detectors.
The range of the individual protons is measured by the number of crossed emulsions
in the detector. Higher traversed material densities correspond to shorter ranges.
are considering to enhance the energy of their beams above the typical 230 MeV by
means of a linac booster to allow performing proton radiography.
In this framework, I am one of the proponents of a novel technique for proton
radiography based on nuclear emulsion films [86]. This development relies on the long
standing expertise of LHEP in Bern on this kind of detectors, mostly for neutrino
physics. This method is different with respect to the standard approaches based on
electronic detectors, silicon trackers followed by calorimeters in particular. Detailed
information on recent developments in proton radiography can be found in Ref. [86]
and only the method proposed by our group is described here.
The basic principle of proton radiography with nuclear emulsion films relies on the
irradiation of an Emulsion Cloud Chamber (ECC) detector made of two-sided nuclear
emulsions interleaved with tissue equivalent plastic plates. The whole detector is
located downstream of the object to be imaged, as shown in Fig 3.11. This is an
end-of-range technique aimed at determining the position of the Bragg peak inside
the ECC. The emulsion detector has to be thick enough to contain the end-of-range
points of all the protons. The difference in density encountered by protons translates
into a difference on the detected range.
The proposed technique is possible due to the recent development of industrially
produced emulsion films and of fast automated scanning analysis systems for modern
neutrino physics experiments, the OPERA neutrino oscillation detector in particular.
Nuclear emulsions have a very long track record as particle detectors and still
represent an important tool for fundamental discoveries [87]. They consist of a gel
with silver bromide (AgBr) crystals where a latent track is formed after the passage
of an ionising particle. Tracks can be visualised and analysed by optical microscopes
after a specific chemical development process performed under controlled conditions.
The chemical development allows the formation of a sequence of silver grains along
the particle track that, with dimensions of 1 µm or less, are well visible by means of
optical microscopes, as shown in Fig. 3.12. Due to their micrometric spatial resolu-
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Figure 3.12: A track produced by a 10 GeV/c pion in an emulsion shows the
typical characteristics of a track originated by a minimum ionizing particle (MIP)
(left). Antiprotons annihilate in nuclear emulsion films and produce the characteristic
stars formed by several tacks mostly due to nuclear fragments. Nuclear fragments
and protons are highly ionizing particles and can be easily distinguished from MIPs
(right).
tion, nuclear emulsions still represent the most precise particle tracking device. Even
within a single 50 µ m emulsion layer, they allow full three-dimensional reconstruc-
tion of particle tracks and the measurement of their energy loss. This is performed
by evaluating the silver grain density along the particle track. In this way, highly
ionizing protons - as the ones used in proton radiography - can be separated from
minimum ionizing particles (MIP). As an example, high ionizing tracks produced by
the annihilation of antiprotons in the same emulsion films used for this work and
analyzed at LHEP are shown in Fig. 3.12 (right). Once exposed, developed and
automatically scanned, the emulsions allow obtaining digital data on which analysis
can be performed by using standard computing techniques.
To test the proposed method in a geometry allowing to keep the main parameters
under control, two phantoms were constructed. As shown in Fig. 3.13, the first
phantom was made of polymethylmethacrylate (PMMA) and presented a simple
1 cm step (step phantom). In this way, protons can traverse only 3 or 4 cm of
PMMA. The second phantom was characterized by a total thickness of 4.5 cm and
contained five 5 × 5 mm2 aluminium rods positioned at different depths in a PMMA
structure (rod phantom).
The emulsion films used for this study consisted of 2 layers of 44 µm thick sensitive
emulsion coated on both sides of a 205 µm thick triacetate base with a surface of
10.2 × 12.5 cm2. As tissue equivalent absorber material, polystyrene plates with
the same transverse dimensions as the emulsions and a thickness of 0.54 mm were
used. The density of polystyrene was measured to be 1.05 ± 0.02 g/cm3.
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Figure 3.13: The step (left) and the rod (right) phantoms used to obtain the first
proton radiography images using a nuclear emulsion film detector.
Figure 3.14: Detector structure: Emulsion film plates are interleaved with blocks
of absorber (not shown) of different thickness. The structure of one emulsion film
is highlighted in the inset together with the two micro-tracks produced in the two
sensitive emulsion layers.
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Figure 3.15: First beam tests of proton radiography with nuclear emulsion film
detectors at the Gantry 1 at PSI. The detector with the step phantom on the top
is highlighted in the inset. The scintillator telescope used to verify the number of
incoming protons is visible on the left.
Simulations for several possible configurations of the ECC were performed using
GEANT3. A proton beam with energy of 138 MeV and with a flat distribution over
the 10.2 × 12.5 cm2 sensitive surface was considered. Particular attention was paid
to optimize the resolution on the determination of the proton range and to minimize
the number of emulsions to be employed. The results of the simulations led to the
design of the ECC detector shown in Fig. 3.14.
This apparatus is divided into two parts. The first one is made of 30 emulsion
films, each interleaved with 3 polystyrene absorber plates, allowing tracking of pass-
ing through protons using a minimal number of films. The second part is composed of
40 films, each interleaved with one polystyrene plate, allowing a precise measurement
of the proton range in correspondence of the Bragg peak. The overall dimensions of
the detector are 10.2 × 12.5 cm2 in the transverse direction, and 90.3 mm along the
beam.
Beam tests were performed with the Gantry 1 at PSI, as shown in Fig. 3.15. It
has to be remarked that a typical clinical beam is not suitable for proton radiography
with this method since the too high intensity will not allow the reconstruction of the
proton tracks. It was calculated that the number of protons had to be limited to
106 on a 10 × 10 cm2 surface, corresponding to 100 protons/mm2. In this way, the
emulsions will not be saturated with a good safety margin. This corresponds to
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Figure 3.16: The number of identified protons as a function of the z coordinate
inside a column of 1 mm2. The fit allows the localization of the Bragg peak.
an average dose of the order of 10−5 Gy. For this purpose, a special low intensity
beam setting was used and an accurate measurement of the number of protons per
unit area performed with a coincidence scintillating telescope before the irradiation
of the ECC. The two phantom-detector systems were exposed to 138 MeV protons
uniformly spread on the surface by means of spot scanning. The gantry was adjusted
to deliver the beam perpendicular to the emulsions.
The emulsion analysis was performed by means of the automatic scanning sys-
tems installed at LHEP. Here a specifically conceived laboratory equipped with six
European Scanning System (ESS) microscopes is active for routine scanning of the
emulsions of the OPERA experiment. Scanning speeds of 10 cm2 per hour can be
reached with prospects for a factor 10 improvement in the next years [87]. The scan-
ning speed represents a crucial point in view of possible routine applications of this
technology in a clinical environment.
Track reconstruction is performed through successive steps. Micro-tracks are first
reconstructed as 3D segments located in each sensitive layer, as shown in Fig. 3.14. At
a second stage, base-tracks are searched for as the lines connecting the two points of
the micro-tracks closest to the plastic base. This method allows to minimize possible
distortions. At the energies used for this measurement, protons are characterized
by an ionization density much higher than MIPs and proton tacks can be efficiently
selected. The background due to other particles is negligible. The proton density
has been measured to be about 70 protons/mm2, in good agreement with the result
obtained with the scintillating telescope before the irradiation.
To obtain proton radiography images of the two phantoms, data were analysed
by subdividing the detectors in columns along the beam direction. The transverse
area of each column was 1 mm2, which represents the size of the pixels of the proton
radiography images. Each pixel must contain enough proton tracks to allow the
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Figure 3.17: The measured proton range as a function of the transverse coordinates
shows a clear proton radiography image of the step (top) and the rod (bottom)
phantoms. The size of each pixel is 1 mm2.
determination of the range with enough precision. About 70 proton tracks were
contained in each pixel, as shown in Fig. 3.16. The variation of the proton density
as a function of the depth has been evaluated for each column in order to determine
the position of the Bragg peak. To calculate the residual range, data were fitted for
each column with the Fermi-Dirac function
f(z) = A− A
e
R−z
S − 1 (3.4)
where z is the coordinate along the beam, A, S free parameters and R represents
the residual range of the protons. One of these fits is reported in Fig. 3.16.
Proton radiography images of the phantoms were obtained by plotting R as a
function of the transverse coordinates, as presented in Fig. 3.17. The shape of the
phantoms was well reproduced, demonstrating the validity of the proposed method.
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Phantom Traversed material (mm) Range in the detector (mm)
PMMA Aluminium Monte Carlo SRIM Data
Step 40 - 76 75.6 ± 0.6
Step 30 - 86 84.8 ± 0.8
Rod 45 - 72 71.9 ± 0.6
Rod 40 5 68 69.6 ± 1.2
Table 3.1: Measured and simulated values for the proton residual ranges.
The residual ranges corresponding to the different traversed densities inside the two
phantoms were measured and good agreement was found with the simulation per-
formed with SRIM. The results are reported in Table 3.1. Errors were evaluated by
the fitting procedure.
As already pointed out, the resolution is critical in proton radiography. For the
proposed method, it depends on two main factors: the size of the pixels in the
transverse plane and the effects due to multiple scattering. Since each pixel must
contain enough protons to allow a precise determination of the residual range (of
the order of 50 particles per pixel) and since the number of protons per unit area
is limited by the saturation of the nuclear emulsion films, the size of the pixel was
naturally chosen to be 1 mm2.
It has to be remarked that the scanning and reconstruction methods used for
this work were those optimized for neutrino physics, where only minimum ionizing
particles with very limited lateral scattering are searched for. By optimizing the full
process to low energy protons used for proton radiography, the use of at least a factor
5 more protons is estimated to be possible. This will allow for smaller pixels, down to
about 0.25 × 0.25 mm2. This value has to be confronted with the intrinsic limitation
due to the multiple scattering. Computer simulations performed with SRIM show
that the radial effects in the transverse plane due to lateral scattering are of 0.5,
1.7 and 3.6 mm for 50, 100 and 150 MeV protons, respectively. The corresponding
residual ranges in the detector are 21.9, 76.1 and 155.0 mm, respectively, typical of
proton radiography. With pixels of 0.25 × 0.25 mm2 the effects of multiple scattering
will be dominant and smaller pixels will not allow any improvement of the resolution.
The proposed technique has a good potential for proton radiography and clinical
beam analysis since modern emulsion detectors are rather cheap and easy to handle.
These characteristics are surely valuable in a clinical environment where daily routine
treatments have absolute priority. A clear limitation of emulsion based detectors is
the absence of a real-time response. Although the speed of modern scanning systems
is steadily increasing with good prospects for the future, it is difficult to imagine that
the speed of this technique could ever compete with expensive and sophisticated on-
line proton imaging electronic devices.
A useful application of nuclear emulsion film detectors is the characterization of
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proton beams during the commissioning phase of proton therapy clinical facilities,
when the purchase and operation of expensive and sophisticated detectors could not
be justified for only this purpose. Along this line, the assessment of the peripheral
dose in the beam halo region of a proton pencil beam has been performed by our
group using the Gantry 1 at PSI [88].
The experience I acquired in nuclear emulsion film detectors by means of this
work, allowed me to contribute to other potential applications of this technique,
either in medical applications [89] [90] or in fundamental physics [91]. In particular,
the possibility of measuring both fast and slow neutrons by detecting proton recoils
in tissue equivalent absorbers interleaved with nuclear emulsion films is now under
study by our group. The first beam tests were performed with fast neutrons at
the CERF facility at CERN [92]. Furthermore, I was one of the promoters of an
international project [93] involving our laboratory and Russian partners centered on
the development of innovative nuclear emulsion film technologies.
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3.3 A BeamMonitor Detector based on doped Sil-
ica Fibres
Beam monitoring is essential in particle accelerator physics. The development, the
commissioning, the upgrade and a reliable daily use of particle accelerators rely on the
knowledge of the beam properties. Diagnostics devices are usually installed in critical
locations, as the injection or the extraction, and in front of the target. This issue is
particularly critical in medical applications, where ion beams are used to irradiate
tumours with millimetre precision or to produce large quantities of radioisotopes
for diagnostics and therapy. It has to be remarked that most of the commonly used
detectors - such as Faraday cups - are destructive and their use is not possible without
interrupting the irradiation.
The wide spread of medical accelerators is giving impulse to research in the field
of beam monitoring instrumentation to fulfill the requirements of precision, compact-
ness, robustness and reliability. Along this line, I dedicate part of my scientific activ-
ity to the development of innovative beam monitoring devices to be installed along
the beam lines either for hadrontherapy or for radioisotope production accelerators.
In this field, I contributed to the development and beam test of a non-interceptive
beam monitor apparatus [94] based on the detection of secondary electrons emitted
by a thin foil traversed by the beam. The foil had a diameter of 70 mm and consisted
of 0.1-0.3 µm of Al2O3 coated on each side with 0.01-0.02 µm of Al. The interac-
tion of the accelerated ions with a so thin foil induces a negligible perturbation to
the beam emittance and produces δ-rays and electrons below 50 eV, conventionally
called secondary electrons (SE). The SEs are ejected from the foil proportionally to
the local beam intensity, with yields calculated to be about 5% and 1% for 20 MeV
and 250 MeV protons, respectively. The yield is defined as the ratio between the SEs
emitted in backward direction and the number of impinging protons. The SEs were
focalized and accelerated to the energy of 20 keV by means of a specific electrostatic
lens. To measure the two dimensional profile and the intensity of the beam, a specific
sensor was located in the focal plane of the lens to detect the 20 keV electrons. A
Micro Channel Plate (MCP) coupled with a phosphor (P47) and read-out by a CCD
was employed. Analog data were digitized by means of a frame grabber. A back-
thinned pixel silicon sensor was also tested. In the framework of a collaboration with
the TERA Foundation, a further development of this detector is presently ongoing
in Bern using the beam line of the new cyclotron.
Although precise and reliable, detectors based on the detection of secondary elec-
trons are relatively large, expensive and require high voltage, sophisticated sensors
and read-out systems. Furthermore, in the case of radioisotope production, radiation
damage due to neutrons represents a delicate issue for the electronics. On the basis
of this experience, I aimed at developing a much simpler device able to provide in-
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Figure 3.18: Principle and general scheme of a beam monitor detector based on a
single moving scintillating doped silica fibre coupled to an optical fibre.
formation on the beam profile and requiring a minimal space on a beam line. These
ideas led to the development of the beam monitoring device based on doped silica
and optical fibres [72] [95] [96], which is described here in more detail.
The working principle of this device is depicted in Fig. 3.18. The light produced
by a single scintillating sensing fibre moved transversally through the beam is trans-
mitted by means of a commercial optical fibre to a photodetector located several
meters away. The position of the fibre is measured and its correlation with with the
signal given by the photodetector is used to obtain the beam profile. Doped silica
fibres are suitable due to their radiation hardness and resistance to the heat produced
by the interaction with the beam. Since they are very fragile, difficult to handle and
have a considerable attenuation length (of the order of several dB/m) their length
has to be limited to about 10 cm in length. To transport the optical signal pro-
duced by the scintillation induced by the impinging beam particles, the doped fibre
is optically connected to a commercial optical fibre. In this way, the signal can be
transported to the photodetector over several meters distance with negligible atten-
uation (of the order of tens dB/km). The photodetector and the related electronics
can be located far from the radiation source, thus eliminating any problem related to
neutron irradiation. The connection between the scintillating and the optical fibre
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Dopant Composition Core Cladding Numerical Length Light
diameter diameter Aperture yield
(µm) (µm) (NA) (mm) (%)
SiO2 (55 %),
MgO (24 %),
Ce3+ Al2O3 (11 %), Unknown 520±20 0.25±0.04 120 0.6
LiO2 (6 %),
Ce2O3 (4 %)
Sb3+ (0.5%) Sb3+:SiO2 461±16 570±20 0.05±0.01 120 0.4
Table 3.2: Main characteristics of the scintillating doped silica fibres used for the
proposed beam monitoring detector. The light yield is expressed in terms of the
fraction of the deposited energy.
is realized inside the vacuum pipe and a remotely controlled linear translation stage
coupled to a vacuum-tight feedthrough or a bellow are used to move the sensing
fibre across the beam. This kind of detector has the advantage of being very thin,
thus requiring a minimal space along a beam line. Furthermore, a sensor based on
fast scintillation is easily adaptable either to pulsed or continuous beams. For the
realization of this detector, the selection of the scintillating fibre and the connection
between the sensing and the optical fibre represent critical issues.
For beam monitoring, plastic fibres have been proposed for hadrontherapy and
are appropriate only for low currents due to their very low resistance to heat. For
high currents of the order of a few µA, Ce3+ doped quartz surfaces were tested up to
temperatures of 1600 K. For this reason, Ce3+ doped silica fibres represent a good
solution. Furthermore, their scintillation light is peaked around 395 nm, a feature
assuring a good coupling with photomultiplier tubes (PMT).
A sample of a few Ce3+ doped silica fibres from an experiment performed at LEAR
at CERN about twenty years ago was used for the first studies. Since this kind of
fibres is no more commercially available, an alternative solution had to be found.
For this purpose, a collaboration with the Institute of Applied Physics (IAP) of the
University of Bern was established in order to explore the possibility to employ doped
silica fibres produced with a method based on a silica preform filled with granulated
oxides. Several doping elements were tested and Sb3+ doped fibres were found to
have properties similar to Ce3+.
While the scintillation properties of Ce3+ doped silica are known, the response
to ionizing radiation of Sb3+ doped fibres was never studied before. To assess the
light yield, tests have been performed with a collimated 370 MBq 90Sr beta source
located about 1 cm away from the sensing fibre. Being the average energy of the
emitted electrons 1.13 MeV, corresponding to a range in glass of 2.2 mm, and the
diameter of the fibre about 600 µm, most of the electrons cross the fibre completely.
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Figure 3.19: The first prototype detector installed on the RFQ accelerator at LHEP.
The linear motion (a) and the optical fibre feedthrough (b) are visible together with
the Faraday cup (c) used for measuring the total intensity of each spill. The V-groove
connection supporting the sensing fibre is contained inside the cross joint (d).
The maximum deposited energy is estimated to be 180 keV. The main characteristics
and the measured light yield for Ce3+ and Sb3+ doped fibres are reported in Table 3.2.
It is important to remark that this kind of fibres allow detecting low intensity beams
down to single particle counting.
A first prototype detector was constructed and tested with the pulsed H− beam
produced by the 2 MeV RFQ accelerator installed at LHEP, as shown in Fig. 3.19.
Aiming at realizing a compact, cost effective and easy to use system, commercial
components have been used whenever possible. The main body of the detector
is an ISO KF-40 cross joint on which a vacuum tight linear motion feedthrough
is mounted. For this first prototype, the movement was realized manually since
radiation protection issues do not represent a problem for 2 MeV H− beams. A 5 cm
long aluminium support is screwed to the linear motion feedthrough to hold the
sensing fibre and to connect it to the commercial optical fibre. Inside this support,
a V-groove is realized to precisely put in contact the two fibres. Contrary to fusion
splicing, this solution allows for an easy replacement of the sensing fibre. Light losses
in the range of 20% - 50% were measured to be constant during the operation of the
device. For read-out and digitization, a photomultiplier and a peak sensing ADC
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Figure 3.20: Measured spectrum of the wavelengths emitted by a Sb3+ doped fibre
irradiated with 2 MeV protons.
were used. During the beam tests, a Faraday cup located downstream the sensing
fibre was used to measure the beam current.
The 2 MeV protons loose all their energy inside the fibre since their range is
about 45 µm in glass, much less with respect to the diameter of the fibre. When
irradiated by the beam, the fibre glows, emitting a very clear blue light signal. The
spectrum of the emitted light is reported in Fig. 3.20 and shows a maximum around
490 nm, allowing for a good quantum efficiency when coupled to a PMT.
For the tests, the beam intensity of the RFQ accelerator was set to about 1011
protons per spill, which, at a repetition rate of 50 Hz, leads to an average total current
of about 0.8 µA. In these conditions about 1010 protons hit the fibre when centred
on the beam. The proton spill produces a very clear signal in the PMT, as shown
in Fig. 3.21. Taking into account the quantum efficiency of the PMT, the signal
was estimated to be generated by about 315000 photons reaching the photocathode
through the 20 m optical fibre.
The emission of scintillation light depends on the temperature of the scintillator
and this phenomenon may have a significant influence on the output signal. To study
this effect, the signals of 5000 consecutive spills were recorded with a fixed position of
the fibre. At the repetition rate of 50 Hz, this corresponds to 100 seconds. The total
charge hitting the fibre is estimated to be 2.7 µC with a total corresponding delivered
dose on the volume of the fibre of 560 kGy. The increase of temperature due to the
energy transferred by the beam is calculated to be 8 K/s for a cold fibre. The heat
is mostly dissipated through black body radiation, being conduction mechanisms
highly suppressed. On this basis, the equilibrium temperature can be calculated.
For the experimental conditions of the beam tests, the equilibrium temperature of
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Figure 3.21: Typical signal produced by a Sb3+ doped fibre during a proton spill.
The nominal duration of the spill is set to about 3 µs. The long tail is due to a
known feature of the RFQ accelerator.
Figure 3.22: Light output for 5000 successive spills of equal intensity. The effect of
heating leads to a decrease of the light output of about a factor five.
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Figure 3.23: Beam profile measured with the Sb3+ doped silica fibre moved in steps
of 1 mm through the beam. The double structure of the beam is a known effect of the
accelerator. The error bars correspond to the rms of the pulse height distributions
and are mainly due to beam intensity fluctuations. The centre of the beam pipe
corresponds to the position of the fibre at 14 mm.
the fibre is estimated to be around 600 K. The measurement performed with 5000
consecutive spills puts in evidence a decrease of the light output of about a factor five
when long lasting irradiations are performed, as shown in Fig. 3.22. This effect may
potentially induce distortions of the beam profile if measurements are taken with
different temperatures of the fibre. However, this effect can be significantly reduced
using a motorized device which allows sweeping the beam in less than one second.
From these measurements, the light loss can be estimated to be 4% in one second
starting from a cold fibre.
Following irradiations lasting more than 100 seconds, it was observed that the
light output returns at the initial value if enough time is allowed for cooling down
the fibre to room temperature. Irradiations with up to 50000 spills - corresponding
to 1000 seconds - were performed and no effects due to permanent radiation damage
have been observed. Further investigations on radiation hardness are ongoing using
the BTL of the Bern cyclotron.
The horizontal beam profile of the 2 MeV pulsed H− beam from the RFQ accel-
erator was measured using Ce3+ and Sb3+ doped silica fibres by moving them across
the beam in steps of 1 mm. The average peak signal was evaluated for each position
by acquiring 1000 consecutive spills after the stabilization of the light output with
respect to the temperature. The beam profile obtained with a Sb3+ doped fibre is
reported in Fig. 3.23 and shows the characteristic beam structure of the RFQ acceler-
ator. A similar profile was measured with the Ce3+ doped fibre. The reproducibility
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Figure 3.24: The second prototype installed in the BTL of the Bern cyclotron.
The remotely controlled motor connected to the linear motion feedthrough (a), the
optical fibre feedthrough (b) and the transparent flange (c) used to observe the fibre
with a CCD are visible. The four finger collimator (d) is used to centre the beam
and the beam dump (e) to measure the total intensity.
of the measurements was found to be within the experimental uncertainties, which
are dominated by the beam fluctuations. As far as the spatial resolution is con-
cerned, the position of the beam can be measured with good precision with this first
prototype detector. The diameters of the sensing fibres used for this device were
around 500 µm (Table 3.2) to assure a sufficient rigidity without the use of a spe-
cific support. The production of Sb3+ doped fibres with a smaller diameter does not
represent a problem and their use could allow for a better precision and produce a
smaller perturbation to the beam.
Following the successful construction and test of the first prototype, the develop-
ment of a horizontal-vertical two-dimensional beam profiler for the BTL of the Bern
cyclotron is ongoing. This device is equipped with a remotely controlled motorized
movement and is optimized to scan the practically continuous beam extracted from
the cyclotron. A second mono-dimensional prototype has been constructed and in-
stalled in the BTL, as shown in Fig. 3.24. The fibre can be monitored by a CCD
camera located in the proximity of a glass flange. Due to the amount of light and
the continuous temporal structure, a photodiode was used as photodetector. The
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Figure 3.25: Signals produced by the 18 MeV proton beam at the intensity of 1 µA.
The Sb3+ doped fibre is moved continuously through the beam with a period of 6 sec-
onds within a spatial range of ±15 mm with respect to the centre of the beam pipe.
The signal produced by the photodiode shows two specular profiles, corresponding
to the left-right and right-left passes. The signal is stable and reproducible within
the experimental uncertainties.
first preliminary beam profiles measured with the 18 MeV proton beam at 1 µA are
reported in Fig. 3.25. The beam profile appears very clear over a negligible back-
ground. The specular structure is due to the left-right and right-left passes of the
fibre through the beam. The period was set to 6 seconds and the range of the hor-
izontal movement to ±15 mm with respect to the centre of the beam pipe. In the
profile reported in Fig. 3.25, the beam was deliberately cut-out on one side by acting
on the steering magnet of the BTL in order to intercept part of it with the four finger
collimator. The sharp decrease of the signal shows a resolution below 1 mm. With
this second prototype, beam profiles have been measured in the intensity range from
500 nA to 5 µA.
A research program is under way based on this new kind of beam monitor de-
tector. It is aimed at determining the maximum operational intensity and radiation
hardens properties of the fibres. A complete control system including the motor and
an ADC based data acquisition system is under development. The miniaturization
of the full apparatus represents a long term goal. In the framework of this develop-
ment, new scintillating doped fibres are also under test. In particular, Ta3+ doped
silica fibres have been selected as potential sensing fibres. Their light yield has been
measured to be 0.5%, slightly higher with respect to Sb3+ doped fibres.
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Conclusions and Outlook
Particle accelerators and detectors are fundamental instruments in modern medicine.
Their development for cancer hadrontherapy and for medical imaging by means of
radioisotopes is the focus of actual cutting-edge research programs. I am active
in this scientific domain since ten years, after having contributed to basic research
in particle physics experiments at CERN. Some of my most relevant publications
in the field of particle accelerators and detectors applied to medicine have been
selected for this Habilitation thesis. They contain original contributions and ideas
together with reviews on the status and perspectives of this discipline. The following
list summarizes the scientific contributions, which are discussed and put in their
perspective in Chapters 2 and 3.
• Proton and ion linear accelerators (linacs) constitute a promising solution to
face the challenges of hadrontherapy. They can be coupled to cyclotrons used
for other medical applications to form a new kind of hybrid accelerator de-
nominated cyclinac. I contributed to the study and development of cyclinacs,
in particular to exploit their unique features for advanced spot scanning dose
distribution.
• The new Bern cyclotron laboratory represents a multipurpose clinical and re-
search facility for the production of radioisotopes for PET imaging and multi-
disciplinary research. As one of the promoters of this project, I proposed
the construction of a beam transport line terminated in a dedicated bunker,
which allows performing production and research in parallel. This new facil-
ity is unique in Switzerland and is now fully operational. The first research
programs are ongoing.
• Segmented ionization chambers are suitable for the control of the position, the
shape and the intensity of clinical ion beams. I directly contributed to the
development of specific pixel and strip detectors and studied their application
to spot scanning dose distribution. In particular, I led the design, construction
and test of a strip ionization chamber for the Gantry 2 at PSI.
• Proton radiography is instrumental to determine the range of protons in tis-
sues for an optimum treatment planning in proton therapy. I am one of the
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proponents of an innovative method based on nuclear emulsion film detectors,
which was successfully tested with a clinical beam.
• The control of the beams along the transfer lines is crucial in medical accelera-
tors. For this purpose, I proposed and contributed to develop a beam monitor
detector based on doped silica and optical fibres. In this framework, new scin-
tillating materials have been studied.
Under the auspices and support of the University of Bern, the Laboratory for High
Energy Physics (LHEP) started in 2008 a dedicated research program on medical
applications of particle physics under my guidance and coordination. During this
time, I have been involved in several research projects and collaborations. The main
focus of this activity has been the SWAN project that aims at the realization of
a clinical and research centre of excellence for the production of radioisotopes and
cancer proton therapy at the Bern University Hospital (Inselspital). Along this line,
efforts were concentrated on the new cyclotron laboratory and, in particular, on
the beam transport line dedicated to scientific research. On this basis, research
and training activities are growing and the Bern group is successfully and visibly
assuming a leading role in the field of particle accelerators and detectors applied to
medicine.
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This part contains the reprints of the selected publications to be considered for
the Habilitation. The scientific work as experimental physicist presented here has
been carried out in the framework of the Foundation for Oncological Hadrontherapy
(TERA) at CERN of which I was the Technical Director, and of the research group
on medical applications of particle physics at the Albert Einstein Centre for Fun-
damental Physics, Laboratory for High Energy Physics (LHEP) in Bern of which I
am the coordinatorr. For clarity, this part is subdivided into three Chapters. Chap-
ter 4 is dedicated to innovative particle accelerators for hadrontherapy based on
cyclotrons and linacs, and to the new Bern cyclotron laboratory and its research
beam line. Chapter 5 presents the design, construction and test of three innova-
tive particle detectors for medical applications of accelerated ion beams, which were
developed under my coordination. Chapter 6 contains the reprint of three review
papers in which I presented the status of hadrontherapy and drew the lines of its
future scientific and technological developments.
The list of the selected publications is reported here below, together with a short
comment on my contribution.
Chapter 4 - Particle Accelerators for medical Diagnostics and Therapy
• U. Amaldi, S. Braccini and P. Puggioni, Linacs for hadrontherapy, Reviews of
Accelerator Science and Technology (RAST) Vol. 2 (2009) 111.
This paper is focused on the advantages of linacs for cancer hadrontherapy
and contains the original scientific work preformed under my coordination on
Cyclinacs for advanced beam scanning.
• U. Amaldi, S. Braccini et al., Accelerators for hadrontherapy: from Lawrence
cyclotrons to linacs, Nucl. Instrum. Meth. A 620 (2010) 563.
The presented work represents an extensive summary of the achievements of the
TERA Foundation obtained under my coordination as Technical Director. In
particular, it contains original achievements on linacs and cyclinacs for carbon
ion therapy. As current practice in particle physics, all the contributors are
listed in alphabetical order. I am the corresponding author.
• S. Braccini et al., The new Bern cyclotron laboratory for radioisotope produc-
tion and research, Proceedings of the second International Particle Accelerator
Conference (IPAC2011), San Sebastia´n, Spain (2011) 3618.
This paper describes the new Bern cyclotron laboratory with its external beam
line for research that I proposed in 2007 and was designed and realized under
my coordination. I am the corresponding author.
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• S. Braccini, The new bern PET cyclotron, its research beam line, and the devel-
opment of an innovative beam monitor detector, American Institute of Physics
(AIP) Conf. Proc. 1525 (2013) 144.
This paper followed an invited presentation at the 22nd International Con-
ference on the Application of Accelerators in Research and Industry (CAARI
2012) where I described the commissioning of new Bern cyclotron laboratory
with emphasis on the optimization of the beam transfer line for research activ-
ities.
Chapter 5 - Particle Detectors for medical Applications of Ion Beams
• S. Braccini et al., MATRIX: an innovative pixel ionization chamber for on-
line beam monitoring in hadrontherapy, Astroparticle, Particle, Space Physics,
Radiation Interaction, Detectors and Medical Physics Applications, Vol. 3,
World Scientific (2006) 677.
The described achievements were obtained under my coordination within the
collaboration involved in the construction and tests of the MATRIX detector. I
am the corresponding author.
• S. Braccini et al., First results on proton radiography with nuclear emulsion
detectors, Journal of Instrumentation 2010 JINST 54 P09001.
Based on the worldwide recognized expertise of LHEP on nuclear emulsion
technologies, the described achievements were obtained under my coordination
within the research group on medical applications of particle physics. I am the
corresponding author.
• S. Braccini et al., A beam monitor detector based on doped silica and optical
fibres, Journal of Instrumentation 2012 JINST 7 T02001.
Following my original idea, these achievements were obtained at LHEP under
my coordination within the research group on medical applications of particle
physics. I am the corresponding author.
Chapter 6 - Highlights on Hadrontherapy
• S. Braccini, Progress in Hadrontherapy, Nuclear Physics B (Proc. Suppl.) 172
(2007) 8.
This paper followed an invited presentation at the 10th International Confer-
ence on Innovative Particle and Radiation Detectors where I was asked to give
a review of cancer hadrontherapy, with particular focus on accelerators and
detectors.
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• S. Braccini, Scientific and Technological Development of Hadrontherapy, As-
troparticle, Particle, Space Physics, Radiation Interaction, Detectors and Med-
ical Physics Applications, Vol. 5, World Scientific (2010) 598.
This paper followed an invited talk I gave in the plenary session at the 11th
ICATPP Conference on Astroparticle, Particle, Space Physics, Detectors and
Medical Physics Applications. I was asked to critically review the main achieve-
ments in the field of accelerators and detectors for cancer hadrontherapy and
to outline future scientific and technological developments.
• U. Amaldi and S. Braccini, Present challenges in hadrontherapy techniques,
Eur. Phys. J. Plus (2011) 126: 70.
This invited review paper describes the main challenges of hadrontherapy from
a physicist’s point of view and outlines the main lines of development of the
discipline. I am the corresponding author.
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